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CHARACTERIZATION OF ADIPOSITY AND INFLAMMATION GENETIC 
PLEIOTROPY UNDERLYING CARDIOVASCULAR RISK FACTORS IN 
HISPANICS 
Mohammad Yaser (Anwar) 
11/30/2020 
The observed overlap between genetic variants associated with both adiposity and 
inflammatory markers suggests that changes in both adiposity and inflammation could be 
partially mediated by common pathways. The pervasive but sparsely characterized 
“pleiotropic” genetic variants associated with both adiposity and inflammation have been 
hypothesized to provide insight into the shared biology. This study explored and 
characterized the genetic pleiotropy underpinning adiposity and inflammation using 
genetic and phenotypic observations from the Cameron County Hispanic Cohort (CCHC).  
A total of 3,313 samples and >9 million single nucleotide polymorphisms (SNPs) were 
examined in this study. Mixed model genome-wide association studies (GWAS) were 
performed for 9 phenotypes including C-reactive protein (CRP), Interleukin (IL)-6, IL-8, 
fibrinogen, body mass index (BMI), waist circumference (WC) in males and females, and 
waist to hip ratio (WHR) in males and females (separately). GWAS for WHR and WC 
were meta-analyzed to obtain sex-combined results. Pleiotropy assessment was completed 
using adaptive Sum of Powered Score (aSPU) test. Three genetic loci with evidence of 
pleiotropy on chromosome 3, 12 and 18 were fine-mapped to distinguish the set of likely 
vi 
 
causal variants. Causal mediation analysis was used to assess whether likely causal variants 
were independently associated with both inflammation and adiposity.  
At least 3 signals, on chromosomes 3, 12, and 12, were identified that suggested the 
presence of SNPs with strong pleiotropic p-values (< 5 × 10−6). The fine-mapping of these 
three suspected pleiotropic regions distinguished 22 variants with posterior causality 
probabilities greater than 50%. The mediation analysis indicated that rs60505812, on 
chromosome 3, was independently associated with both an inflammatory marker (IL-6) 
and an adiposity measure (BMI). For the variant rs73093474, on chromosome 12, results 
indicated both a direct association with CRP and an indirect association (via WHR).  
The identification of likely pleiotropic variants indicated that 1) a considerable degree of 
overlapping genetic pleiotropy exists between adiposity and inflammation, and 2) evidence 
exists to support both the direct and indirect pleiotropy. The results showed the potential 
of these genetic variants to provide biological insight, intended to improve the 
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INTRODUCTION AND BACKGROUND 
This chapter presents background information on the epidemiologic, pathophysiologic 
and genetic aspects of obesity and associated cardiovascular risk factors, particularly in the 
context of Hispanic/Latino populations. Biologic discussions focus on  associations and 
functional overlaps between adiposity and inflammation that promote adverse 
cardiovascular outcomes. The review emphasizes gaps in the current literature on genetic 
factors underpinning biologic pathways affecting adiposity and inflammation in 
Hispanic/Latinos, and concludes with the scientific aims of the dissertation work.  
1. Epidemiology 
1.1. Obesity trends 
Although a struggle with undernutrition has been a defining feature for most of human 
history, the industrial revolution resulted in the explosive growth of agricultural 
productivity over the last two and half centuries, resulting in a relative abundance of food 
that has significantly contributed to the well-being of societies. Records from industrialized 
countries show that the average height1 and weight2 of individuals has progressively 
increased throughout the 19th and the first half of the 20th century.  
However, continued uptake of high calorie foods coupled with changes in lifestyles and 
environmental settings, especially during the latter half of the 20th century, have gradually 
tipped the balance toward obesity. The populations in more wealthy parts of the world have 
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begun to gain weight at levels that are disproportionate to the gains made in height3. At the 
dawn of the new millennium, humans passed a landmark point when adults with excess 
weight outnumbered those who were underweight4. Today, obesity is a major public health 
challenge5.  
Even though obesity figures vary between countries, due to differences in socioeconomic 
characteristics and the speed of epidemic transition [away from infections’ dominated 
landscape toward the rise in metabolic diseases]6, recent decades have seen linear upward 
trend in the prevalence of overweight and obesity almost everywhere7. Between 1980 and 
2013, the average proportion of overweight increased by one-third, in both men and 
women, globally8. A review of over 2,000 population-based studies published between 
1985 and 2017 showed that body mass index (BMI) values, defined as weight (in 
kilograms) over height squared (in meters), increased from 22.6 to 24.7 in women and from 
22.2 to 24.4 in men9.  
This rising trajectory in obesity appears to include all age groups. Based on a pooled 
analysis of approximately 2,500 population-based studies, including 128 million 
individuals aged 5 years and older, the average estimated global prevalence of obesity 
among children has increased 8-fold, from just under 1% in 1975 to approximately 8% in 
201610. In the United States, estimates have shown that approximately 69% of adults are 
classified as overweight (BMI ≥ 25), 35% are obese (BMI ≥ 30), and 14.5% are moderately 
to extremely obese (BMI ≥ 35) 11. 
However, average numbers do not reflect the underlying complexities associated with 
obesity prevalence. At the subnational level, significant disparities in the distribution of 
overweight and obesity exist among various ethnic and socioeconomic12,13. A higher 
3 
 
proportion of Hispanic Americans appear to suffer from overweight and obesity, with a 
greater than 12% increase in the prevalence of overweight and a greater than 21% increase 
in the prevalence of all-type obesity compared with the overall mean for the adult 
population (>20 years age)11. A review of the National Health and Nutrition Examination 
Survey (NHANEs) biannual reports between 1999-2018 revealed larger annual percentage 
point increases in obesity among Hispanics compared with non-Hispanics, with severe 
obesity now occurring in over 10% for this ethnic group14. It should be noted that increase 
in obesity is not limited in Hispanic Americans but similarly noted in other countries with 
majority Latino populations15, with unequal distribution that disproportionately affects 
those at lower levels of socioeconomic status16.  
1.2. Public health significance 
Increased obesity is an important public health issue due to the associations between 
obesity and various adverse health outcomes17,18. Central obesity, in which the excessive 
accumulation of weight occurs in the abdominal region, is a known risk factor for serious 
diseases19, and has been associated with insulin resistance20, high blood pressure21, 
dyslipidemia22, and metabolic hormones disorders18. These metabolic disorders, in turn, 
increase susceptibility to cardiovascular diseases23, often with fatal consequences.  
Unsurprisingly, given the elevated trends in obesity, the prevalence of cardiovascular risk 
factors is also higher among ethnic minorities, including Hispanics24. For example, the age-
adjusted prevalence ratio of diabetes was >2.5 times higher in Hispanics than in non-
Hispanic whites, in one recent survey25; another study suggested that as many as two in 
three Hispanic adults present with abnormal levels of lipids26.  
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Yet, despite the elevated prevalence of various metabolic risk factors, Hispanics also 
appear to have longer life spans and suffer from lower rates of cardiovascular disease-
associated mortality27,28. Statistics from NHANES from 1988 to 2006 vividly illustrate the 
reduced mortality rate in this group compared with other groups (e.g. Hazard ratio 0.42 vs 
Non-Hispanic Whites among ≥ 50 years old)29. Various factors, including immigration of 
healthy individuals27, a legume- and fruit-based dietary pattern, supportive social and 
family structures, the unreliability of the data, and the Salmon bias, which describes the 
tendency for older, unhealthy individuals to return to their original countries30, have been 
suggested as possible explanations for this “Hispanic paradox”31.  
Whether this paradox exists32 and what factors may explain it is an active area of 
research, rife with arguments and counterarguments. However, the persistence of a lower 
mortality rate among Hispanics, even in studies that have attempted to control for 
socioeconomic factors33, has resulted in a focus on the important but sparsely explored 
contributions of genetic ancestry to this paradox34.  
2. Pathophysiology  
Increasing body weight steadily taxes the body’s physiological capacities35, eventually 
causing major disorders36. Altered pulmonary parameters37, the expansion of cardiac 
output, increased sympathetic nervous system activities38, increased systolic and diastolic 
blood pressure39, elevated sodium retention40, and the attenuation of immunity41 are some 
of the notable consequences of increased body weight. The pathophysiological changes 
that are triggered by excess weight can affect multiple organs and systems, leading to 
adverse outcomes in brain42, reproductive43, liver44, and kidney functions45, among others.  
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The deleterious effects on the heart and vascular system are particularly concerning46 
because the obese population features a significantly higher mortality rates associated with 
cardiovascular diseases, with one studying reporting a hazard ratio as high as 2.21 among 
those with body mass index (BMI)≥40, compared to normal weight (20≤BMI<25) 
individuals47, even as the BMI is not an ideal predictor of the cardiovascular diseases48. 
The United States National Vital Statistics report in 2017 showed that 23% of all deaths 
could be attributed to heart diseases, making heart disease the top-ranked cause of 
mortality, ahead of all types of malignant neoplasia49.  
2.1. Obesity-cardiovascular system association mechanisms 
The precise mechanisms that link obesity with cardiovascular risk factors remain 
unknown, although many hypotheses have been generated50-52, all of which could partially 
or substantially contribute to this association. For instance, one proposition is that the 
obesity-induced decrease in insulin sensitivity promotes increased arterial stiffness53. 
Insulin-resistance reduces endothelium-dependent vasodilation53, possibly through nitric 
oxide-dependent processes that act as physiological regulators of vascular tone54 and 
induce smooth muscle proliferation and migration54. 
Abnormal kidney function and the resulting impacts on elevated blood pressure and 
hemodynamic imbalance is another area of research focus55. Obesity increases tubular 
reabsorption, shifting pressure natriuresis (sodium excretion) toward higher blood pressure 
to maintain the water-sodium balance56. Elevated reabsorption appears to be mediated 
through the activation of the renin-angiotensin system, and the buildup of adipose tissue 
around the kidney and increased extracellular matrix levels within the kidney can cause 
medullary compression, altering the intrarenal mechanical forces57 (Figure 1.1). Obesity is 
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also associated with tangible renal vasodilation and higher glomerular filtration rates58, 
which can increase sodium reabsorption.  
Nonetheless, the focus of the majority of research  on obesity and cardiovascular risk 
factors has been on adipose tissue. Changes in the local distribution59 and metabolic 
characteristics of adipose tissue60,61 play decisive roles in the association between obesity 
and adverse cardiovascular outcomes. The regulation of adipose tissue is a delicate process, 
and disruptions in adipose regulation can result in detrimental health effects, particularly 
in visceral and ectopic adipose tissue, which are particularly sensitive to overnutrition62. In 
response to sedentary lifestyle conditions63, genetic predispositions64 or exposure to 
malignant environmental factors65, the rapid or sustained accumulation of lipids can disrupt 
the differentiation of preadipocytes and accelerating the formation of larger, dysfunctional 
adipocytes66,67 (Figure 1.2). 
2.2. Adiposity and inflammation 
The associations between obesity and metabolic irregularities are often attributed to 
inflammatory responses induced by adipose tissue68,69. In humans, similar to other 
mammals, adipose tissues exist in two forms: white adipose tissue and brown adipose 
tissue. Brown adipose tissue is found primarily in (human) neonates and plays a significant 
role in the regulation of body temperature through non-shivering thermogenesis during the 
earlier years of life. White adipose tissue, on the other hand, is thought to be the site of 
energy storage when a positive imbalance exists between energy intake and expenditure. 
Adipose tissue also contains preadipocytes, endothelial cells, fibroblasts, leukocytes, and 
macrophages. Energy, primarily in the form of glucose and fatty acids, is converted to 
lipids through a well-characterized lipogenesis process70.  
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Adipocytes can expand in size (hypertrophy) and numbers (hyperplasia) to accommodate 
increased fat storage needs in cases of positive energy imbalance71 to maintain energy 
homeostasis. Adipose tissue expansion creates the need for insulin, which is an essential 
peptide secreted from beta-cells in the pancreas that regulates the absorption of glucose 
from the bloodstream into the liver, skeletal muscles, and adipocytes.  
Sustained anabolic activities, such as growth and differentiation, necessitate a steadier 
supply of insulin as an adaptive response to excess energy or in response to underlying 
disease. This intensely pushes the closed-loop of the adipocyte-brain axis, which controls 
the feedback process72, and adipocytes respond with increased hyperplasia and 
hypertrophic changes.  
Enlarged adipocytes feature altered lipolytic profiles, which can be attributed to the 
enrichment of regulatory proteins, including lipase and perilipin, which are distal in the 
lipolytic cascade73. These cells have also been shown to be resistant to the lipopenic (blood 
lipid decreasing) actions of leptin74, a hormone that is made in adipose cells (beside 
enterocytes) and contributes to the regulation of energy balance by inhibiting the hunger 
sensation75.  
Ability of enlarged adipocytes to synthesize adiponectin is decreased compared with 
normal adipocytes, which impairs fat oxidation and glucose regulation and amelioration of 
inflammatory activities76. Simultaneously, highly active hypertrophied adipocytes exhibit 
distorted cytokine secretion characteristics77. They also promote noticeable increase  in the 




Adding to the complexity of inflammatory reactions, the physical expansion of cells 
triggers increased blood flow, resulting in the attraction of macrophages through several 
signals, including monocyte chemoattractant protein 1 (MCP1)80 and increased apoptotic 
adipocytes66. In experimental studies, CD8+ T-cells are attracted to and infiltrate obese 
adipose tissue, which, in turn, facilitates the recruitment and activation of macrophages to 
this tissue81. increased macrophage presence in adipose tissue is associated with increased 
obesity82. 
Within pro-inflammatory milieu of expanded adipose tissue, in which increased 
concentrations of macrophages are admixed with lipolytic and apoptotic adipocytes, cross-
talk between these two cell types can promote positive feedback loops, resulting in the 
amplification of adverse metabolic and inflammatory actions, mediated by an increase in 
the levels of circulating inflammation markers83,50 (Figure 1.3). Moreover, adipocyte-
secreted cytokines, including IL-6, are key drivers of C-reactive protein (CRP) production 
in the liver (through direct liver access via the portal system84). As a result, CRP is often 
used as a significant predictor of cardiovascular diseases85.  
Enhanced cytokine levels result in the increased production of free fatty acids, which are 
potent activators of the Toll-like receptor family86. Toll-like receptors are pattern 
recognition receptors that activate a variety of intracellular signaling pathways, including 
the activation of nuclear factor-kappa B (NF-kB) and inflammatory cytokine production, 
which are responsible for activating innate immunity87 and triggering the inception of 
atheromatic processes.  
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2.3. Inflammation as a possible adiposity precursor  
Although most biological research presupposes adiposity to be the trigger for the 
inflammatory process, some indications have suggested that the adiposity–inflammation 
relationship could also move in the other direction. For example, compelling evidence 
suggests that inflammation-induced insulin resistance may dysregulate glucose uptake by 
adipocytes and promote or exacerbate the accumulation and inflammation of adipose 
tissue88. Insulin resistance-induced hyperinsulinemia can create anabolic pressure89, 
triggering hyperplastic and hypertrophic changes in adipose tissues to alleviate glucose 
accumulation90. If sustained, these cells ultimately reach a tipping point, when further 
anabolic pressures cannot be accommodated due to constraints on the physical expansion 
of cells and tissues. 
Beside insulin resistance induced adiposity, analysis of inflammatory markers in over 
2,000 non-diabetic, middle-aged men found that the highest levels of inflammatory 
markers at baseline were predictive of weight gain over the 6 years of the study follow-up, 
regardless of body weight at the start of the study91.  
Specific dietary patterns, particularly those high in sugar and saturated fats, have been 
reported to cause inflammation in the hypothalamus, resulting in leptin resistance, a 
precursor event to appetite dysregulation and the altered metabolism of fat and glucose92. 
A similar pattern of leptin resistance was also observed in experimental studies with rats93. 
Microbiota and bacteria-induced inflammation that precedes obesity is an active area of 
research, in which structural changes in the permeability of the gut may promote the 
selective uptake of nutritional components94-96.  
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2.4. A case for overlap in the underlying functional mechanism  
Some of the relationships described above have been suggested to form a circular loop, 
in which weight gain causes inflammation, resulting in metabolic/structural alterations that, 
in turn, cause further fat accumulation. Such self-sustained feedback mechanisms have 
previously been suggested97 and merit attention in adiposity–inflammation association 
studies (Figure 1.4).  
Although most of the studies included in this review implicitly assume that these 
feedback mechanisms move towards a pathophysiological direction, the origin of the 
trigger remains unclear. The sophisticated and complex natures of both inflammation and 
adiposity suggest a nuanced underlying mechanism, one that may be induced by certain 
changes in either adiposity or inflammation and may be mediated by common molecular 
pathways that result in variations in both domains, indicating a level of interrelatedness 
between these two domains, linked by some shared biological underpinning. A 
comprehensive investigative approach remains necessary to discern these relationships by 
incorporating traditional laboratory-based assessments with genetic insights at both the 
population and molecular level.  
3. Genetics of obesity and inflammation 
Although the role played by genetics in the expression of biological traits has long been 
accepted, scientists have only recently begun to contemplate the exact mechanisms that 
link heritable elements with the expression of physiological98 and other phenotypes99. The 
widespread availability of DNA sequencing and genotyping techniques and the 
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development of statistical tools that take advantage of ever-increasing computational 
power has resulted in the advent of GWAS.  
In contrast with approaches that test pre-specified regions, the hypothesis-independent 
GWAS approach scans millions of variants throughout the genome, examining their 
associations with phenotypic variations. First adopted in early 2000, GWAS-based studies 
have experienced exponential growth, providing significant insights into our understanding 
of the genetic underpinnings of diseases100,101.  
To date, GWAS Studies have provided strong evidence for associations between genetic 
variants and adiposity102-104 as well as inflammatory markers105-109, indicating the potential 
complexity and variability of the underlying biological networks that mediate phenotypic 
expression, either directly or in tandem with other factors.  
3.1. Genetic overlaps between adiposity and inflammation 
With the increased availability of GWAS summary results, a number of genomic regions 
that were originally reported in association with obesity were later found to be similarly 
associated with inflammatory traits. Evidence for such intersections has also been reported 
for asthma and obesity110. In an experimental study, high levels of inflammatory markers 
were observed in mice carrying genes that harbored alleles associated with increased 
obesity risk111. Concurrent inflammatory effects were also reported in studies where the 
expression levels of adipose tissue genes were regulated112,113. More specifically, single 
nucleotide variants (SNPs) located in LRRF1P1106, FTO114,115, AdipoQ116, CSN1S1117, 
FDFT1, and PCCB107 were suggested to be associated with both inflammatory markers 
and obesity traits. The reverse was also observed, with genes including IL6, which encodes 
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an inflammatory cytokine, found to affect energy balance118 and TNF interacting with 
adiposity119.  
In addition, the phenotypic synergy between adiposity and inflammatory traits, including 
the expression of CRP120, interleukins120, and other cytokines121, has been consistently 
observed. This phenotypic synergy provides ample evidence for the existence of 
overlapping functional pathways that underly both domains and are likely to be affected 
by genetic variants. Termed pleiotropic variants in the scientific literature122, these multi-
effect variants could help explain the underlying mechanisms that result in correlated 
phenotypic expression. The finding that seemingly distinct but co-expressed phenotypes 
may share genetic pathways highlights the relevance of pleiotropy in understanding these 
complex traits123.  
3.2. Study of pleiotropic variants offers novel biologic insight 
Pleiotropic variants are known to be pervasive124 and have the potential to do the 
following. (1) Clarify the molecular functions of phenotype-associated loci and identify 
common functional pathways between multiple phenotypes124. (2) Inform the classification 
and treatment of patients. Although current treatment strategies combine therapies directed 
at distinct cardiovascular disease risk factors, an alternative approach, which may 
potentially be informed by the investigation of pleiotropy, is the identification and targeting 
of mechanistic “common denominators.” Similarly, drugs that are developed to treat a 
specific disease phenotype could be repurposed if a common therapeutic target was 
identified. (3) Prioritize variants for functional follow-up. The vast majority of GWAS-
identified variants are not causal but, instead, are correlated with true causals variant 
through linkage disequilibrium (LD)125,126. However, distinguishing associations that 
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represent shared effects for a single variant from among multiple independent variants that 
co-localize is crucial for interpretations of mechanistic models127. (4) Increase the 
statistical power of novel locus discovery128. Inconsistencies between estimated and 
explained heritability129 and substantial proportions of variance can be explained when 
considering all GWAS SNPs130,131. The number of GWAS-identified novel loci continues 
to increase as sample sizes increase128, which suggests that multiple loci remain 
unidentified. Previous studies by several research groups132,133 have demonstrated how 
harnessing pleiotropy can increase the statistical power of novel locus discovery.  
4. Gaps in adiposity–inflammation pleiotropy research 
4.1. Inadequate number of studies 
Despite their potential for illuminating the origin of complex traits, including 
inflammation and adiposity, the exploration of pleiotropic variants has been limited, and 
the underlying mechanisms associated with these SNPs remain largely uncharacterized. 
The studies referenced in the previous section constitute a substantial proportion of the 
existing literature on adiposity–inflammation pleiotropy, which highlights the need to 
perform additional research and in combination with functional studies.  
4.2. Methodological challenges 
In most instances, whether overlaps in the GWAS-identified loci reflects mediated 
pleiotropy (i.e., an SNP influences adiposity, which, in turn, affects inflammation)127 or 
represents biological pleiotropy, with distinct SNP effects on each phenotype remain 
unresolved. Restricting attention to genome-wide significant or even suggestive SNPs will 
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typically underestimate the extent of pleiotropy, as SNPs with more modest effects will be 
excluded134.  
Interrogating pleiotropy by comparing phenotype-specific SNP lists can often fail to 
distinguish between SNPs that represent biological pleiotropy from SNPs that co-localize 
due to (1) spurious associations, which may reflect ascertainment bias where SNP 
associates with co-occuring trait135, phenotypic misclassification136, allelic structure, or 
shared controls137; or (2) reflect ambiguity in mapping the true underlying causal variant, 
particularly with non-coding variants that have tissue specific effects138.  
4.3. Limited inference 
Methodological issues and the inadequacy of current pleiotropy research are not the only 
factors hindering further exploration and functional characterization of multi-trait 
associated variants. Most existing GWAS and pleiotropic studies have been performed on 
largely European ancestry populations. The confinement of investigations to specific 
groups139,140 can create a biased view of human variation and hinders the translation of 
genetic associations into clinical and public health applications that are relevant for all 
populations141. In addition, these studies fail to leverage the genetic architecture of 
racial/ethnic minority populations and miss opportunities to pinpoint unique variant-gene 
combinations. 
The conclusions formed from existing studies may warrant limited generalization given 
the differential distribution of inflammatory markers associated with comparative adiposity 
configurations142, patterns of fat accumulation143,144, and the prevalence of cardiometabolic 
abnormalities in minority groups, such as Hispanics/Latinos145. These differences have 
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been persistently observed in various settings; for instance, in the multiethnic Insulin 
Resistance Atherosclerosis Study (IRAS) cohort, Hispanic participants were found to 
present significantly higher concentrations of circulatory CRP and plasminogen activator 
inhibitor-1 (PAI-1) in adiposity adjusted analyses146. Ethnic disparities were also identified 
for adipokine levels between participants in the Study of Women’s Health Across the 
Nation (SWAN), even after accounting for adiposity measures142.  
Given the cross-phenotypic effects of genetic loci associated with adiposity147, the 
ancestry-specific genetic architecture may underpin the disparities observed in adiposity-
associated cardiometabolic risk factors and associations between ethnic groups148.  
Therefore, the investigation of genetic underpinnings is critical for an understanding of 
the mechanisms that result in disparities in cardiovascular risk factors between 
Hispanic/Latino populations and other populations. The handful of existing assessments 
involving minorities have limited inferential utility, largely due to smaller sample sizes, 
which have unsurprisingly resulted in contrasting conclusions149,150.  
Uncovering the genetic underpinnings of ancestry-specific inflammatory pathways that 
link central adiposity with the metabolic abnormalities that are considered precursors to 
deleterious cardiovascular outcomes is essential in this population. A genome-wide, 
systematic, and comprehensive evaluation of pleiotropic genes that overlap between 
adiposity and inflammation phenotypes in Hispanic/Latino populations is necessary to 
identify these genetic effects. 
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4.4. Adiposity–inflammation pleiotropy study in Hispanics/Latinos 
The tri-admixed nature of Hispanic/Latinos captures genetic variations from Amerindian, 
African, and EU populations151, and facilitates the detection of variants that are 
infrequent/monomorphic in more homogeneous populations, as demonstrated 
previously152,153.  
Hispanics/Latinos also present opportunities for estimating causal probabilities for 
GWAS inferenced variants (fine-mapping)154, due to shorter shared haplotypes compared 
with EU populations155. Fine-mapping is even more powerful in the context of data from 
non-European ancestry populations156, greatly reducing the number of SNPs identified for 
functional evaluations157,158.  
The provision of new genetic and molecular insights into such complex traits in this era 
of precision medicine is intended for clinical utility and the development of effective 
preventive strategies designed to improve the cardiovascular health of Hispanics and, by 
extension, all ethnic groups through the reduction of associated metabolic risk factors.  
5. Study Rational 
Assuming that adiposity and inflammation are interrelated manifestations of biological 
mechanisms, the identification and study of the genetic variants that underpin such 
mechanisms can enable the examination of phenotypic classifications, the repurposing of 
pharmaceutical interventions, and ultimately, cardiovascular disease prevention. The 
conceptual framework for the study is graphically illustrated in Figure 1.5. 
The selection of a Hispanic population with unique, tri-admixed genetics will highlight 
functional variants and their associated pathways at the molecular level.  
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6. Aim of the Study Project 
We aim to characterize the adiposity- and inflammation-associated genetic pleiotropy 
underpinning cardiovascular risk factors in Hispanic Americans by using observations 
from the Cameron County Hispanic Cohort (CCHC). By utilizing phenotypic and 
genotypic data, combined with advanced statistical approaches, SNPs that are significantly 
associated with adiposity and inflammatory traits will be explored, fine-mapped to identify 
functional variants, and sorted to distinguish biological and pleiotropic variants.  
The specific aims of this dissertation are:  
1) Identify loci with potential evidence for pleiotropy across inflammation, overall 
obesity, and central adiposity domains in a Hispanic/Latino population. 
By employing measures of overall obesity (BMI), central obesity (waist to hip ratio, waist 
circumference), and inflammatory traits (CRP, Fibrinogen, IL-6, and IL-8 levels) obtained 
from blood samples159, the study intends to perform the following:  
a. Estimate genome-wide univariate associations between approximately 10 million 
SNPs and Aim 1a phenotypes.  
b. Apply the adaptive sum of powered score (aSPU) test160 to the Aim 1a summary 
statistics to identify potentially pleiotropic loci across phenotypic domains. 
2) Leverage allelic associations and variants’ functionalities to prioritize SNPs for 
in-depth statistical and experimental interrogation. 
a. Using PAINTOR161 and FINEMAP162 to conduct fine-mapping on the loci identified 
in Aim 1b, prioritize SNP candidates for additional statistical and functional evaluation.  
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3) Distinguish SNPs with evidence for biological pleiotropy. 
a. Application of pathway analysis to differentiate Aim-2 prioritized SNPs with evidence 
of biological pleiotropy (e.g., variants that influence several independent phenotypes) from 
mediated pleiotropy.  
The specific hypotheses are that: (1) genome-wide assessment will highlight loci that 
potentially affect multiple inflammatory- and adiposity-associated phenotypes (Aim 1). (2) 
At these possibly pleiotropic loci, fine-mapping informed by population structure and 
functionality will pinpoint functional SNP candidates (Aim 2). (3) Some of these 
candidates will illustrate evidence of biological pleiotropy (Aim 3).  
By considering obesity and inflammation to be interrelated manifestations of biological 
mechanisms, rather than in isolation, this proposal will pave the way towards gene and 
functional variant identification, enabling research examining etiology-based phenotype 
classification, drug repurposing, and, ultimately, cardiovascular disease prevention.  
A Hispanic-Latino population was intentionally selected as a population with a high 
burden of disease, and that is often underrepresented in genomic studies, which ensures 
that our proposed study is innovative, particularly as next-generation sequencing, precision 
medicine, and direct-to-consumer genetic testing become more commonplace, in the 








7. Tables and Figures 
Figure 1.1.  Obesity increases extracellular matrix levels within the kidney and may cause 
medullary compression, altering the intrarenal mechanical forces. This structural change 
increases reabsorption of sodium in the Henle Loop and conversely reduce sodium levels 
in Macula denasa. The latter event would trigger renin-angiotensin system and increases 
glomerular fiteration rate and renal blood flood, resulting in elevated extracellular fluid 
volume, increased hemodynamic load and ultimately hypertension which is a precursor to 













Figure 1.2. Adipocytes expand and replicate to store positive energy balance in the shape 
of lipids. The rapid or sustained accumulation of lipids  can disrupt the differentiation of 
preadipocytes and accelerating the formation of larger, dysfunctional adipocytes that have 
altered hormonal and inflammatory profile (Van Gaal et al., 2006). 
 
 
Figure 1.3. Hypertrophied adipocytes upregulate production of proinfommatory cytokines, 
including IL-6, that are key drivers of C-reactive protein (CRP) production in the liver 
(through direct liver access via the portal system. Within this inflammatory milieu, 
increased concentrations of macrophages admixed with lipolytic and apoptotic adipocytes 
promote positive feedback loops, resulting in the amplification of adverse metabolic and 









Figure 1.4. Functional ovrelapp and feedback loop has been suggested where weight gain 





































This chapters present information on study population, quality control procedures, and 
statistical approaches proposed for the data analysis. The review highlights the study 
setting and the recruitment process. Discussions entail descriptive analysis of genetic and 
phenotypic observations, variable selection, genetic data quality assessment and 
imputation, exclusion/inclusion criteria and outlier examinations. Mathematical summaries 
of the proposed statistical methods are provided in the latter part of the chapter.  
1. Study Setting 
Cameron County, in the state of Texas, is the southernmost county in the US. According 
to a recent Population and Housing Units Estimates report, provided by the US Census 
Bureau (in 2020) , the total population of the county is 423,163 individuals (census.gov), 
with the large majority (approximately 88%) self-identifying as Hispanic or Latino.  
The county harbors a high percentage of residents who were born in Mexico164, are 
economically classified as low-income, and have lower educational attainment than the 
national average164. Based on data from 2004-2015 period, only one-third of the individuals 
in this county were covered by any type of health insurance program165. The prevalence of 
obesity (57%), prediabetes (32%), diabetes (28.7%), hypertension (31.0%), and 
hypercholesterolemia (50.1%) among this population suggests high susceptibility to 




The CCHC study started in 2004 and continually developed and expanded ever since. 
This study is intended to be a “Framingham-like” open enrollment observational cohort 
consisting of a Hispanic population, providing a setting for the exploration of a variety of 
health-related topics.  
This initiative is primarily funded by the National Institute for Minority Health 
Disparities (NIMHD). Current research involving this cohort includes the study of diabetes 
risk, cardiovascular disease, peripheral artery disease, liver disease, cancers (liver/breast), 
mental health, intervention studies, genomics, immunology, imaging/elastography, clinical 
trials, and economics.  
1.2. Recruitment process 
Recruitment is ongoing, and the number of participants is now approximately 5,000 
individuals; Medical examinations and interviews are performed at Clinical Research Units 
(CRUs) in both Brownsville and Laredo, Texas. The first round of recruitment included 
2,000 participants and was performed between 2004–2007.   
Although most participants have been adults, a small pediatric group (8-17 years old) 
was also enrolled in the study. Regular follow-up visits, performed every 5–10 years, are 
planned for participants recruited at baseline to allow for longitudinal data collection, using 
nested study designs, and the implementation of clinical trials.   
Using a 2-stage, stratified sampling design, census tracts were classified into 4 strata 
according to income level. Targeted sampling was performed on the first (lowest) and third 
socioeconomic strata. From 42 clusters in the lower socioeconomic stratum, 11 tracts were 
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selected for random sampling; similarly, 11 tracts were selected from among the 39 clusters 
in the higher socioeconomic stratum164. The highest stratum was omitted because it 
contained predominantly “winter Texans,” who were primarily retired visitors from the 
northern United States and Canada and were less likely to be Hispanic.  
All households within a selected census block were invited to participate in the study. 
Overall, 71% of approached households elected to participate, with more participants from 
the lower SES stratum than from the upper stratum (78% vs. 63%); then, one person from 
each household was randomly recruited for the study. The recruitment process is currently 
in the second stage and is ongoing. Recruiters are from the local population and are 
bilingual and bicultural. Each randomly selected household was visited at least 5 times.  
The institutional review boards at the University of Texas Health Science Center and the 
University of Texas at Brownsville reviewed and approved the protocol. They also 
approved the informed consent forms, which included permission to collect and store de-
identified data and specimens for this and other studies. 
2. Data Collection 
Those who agreed to participate were then invited to visit a CRU for examinations. All 
questionnaires and explanations were scripted in both English and Spanish, and 
participants were not asked to fill out any forms. Questionnaires and examinations were 
conducted by nurses and field workers, who were trained in good clinical practices, in 
accordance with the National Institutes of Health requirements.  
2.1. Anthropometric measures  
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The weights of the participants were measured with their shoes removed and recorded to 
the nearest 0.2 kg using a Seca digital scale (Birmingham, UK). Standing height (cm) was 
measured measured and recorded to the nearest 0.2 cm using a Perspective Enterprises 
stadiometer (Portage, MI, USA) and weight (kg). BMI was measured by dividing the body 
weight over the square of the height in meters (m2); waist circumference (visceral 
adiposity) was measured to the nearest 0.2 cm at the level of the umbilicus, with 
participants in a standing position and breathing normally164. All measurements were 
performed twice, and the mean value was recorded in the dataset.  
2.2. Inflammation biomarkers  
Participants were asked to fast for at least 10 hours overnight before their visit to the 
CRU, which was located centrally at Valley Baptist Medical Center. After confirming the 
duration of their fast, blood samples were obtained for subsequent laboratory 
measurements and DNA sequencing; participants who had not fasted were rescheduled164. 
Specimens were aliquoted and frozen at −80°C. CRP levels were analyzed at a Clinical 
Laboratory Improvement Amendment (CLIA)-certified laboratory. IL-6 and IL-8 which 
are markers of chronic, low-grade inflammation, were measured using a multiplex enzyme-
linked immunosorbent assay (ELISA, Milliplex Map, Millipore, CA, USA) and read in a 
Luminex 200 system (Luminex Corp., Austin TX).  
2.3. Genetic measurements 
Genetic measurements were completed at the Vanderbilt University Medical Center 
genotyping core facility, VANTAGE. Genotyping was performed using a MEGA-Ex 
panel, which included >2 M variants. MEGA also incorporates 400K low-frequency and 
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rare disruptive variants that were originally derived from a pan-ethnic panel of 40K whole-
exome sequenced (WES) individuals and a heavily curated catalog of > 40K clinical 
variants. Measurements were recorded in binary PLINK format 168. 
3. Exploratory Analysis of Genetic Measurements and Quality Control 
Out of 2,038,233 total genotyped variants, 1,842,794 single-nucleotide polymorphisms 
(SNPs) passed initial lab control, whereas the remainder did not perform consistently and 
were, therefore, dropped from the initial data set. 
3.1. Pattern of missingness  
Allelic frequency distribution showed that out of 1,842,794 total variants, slightly greater 
than 50% were classified as rare variants, which are defined as SNPs with minor allele 
frequencies (MAFs) of < 1% (Figure 2.1).  Next, the per variant missingness was assessed 
(Figure 2.2). Although a sizeable proportion of variants (approximately 24%) had a 
maximum of 1% missingness, the proportion of variants with missingness equal to or 
exceeding 5% were negligible (approximately 5%).  
Next, per  sample missingness were examined. The initial exploration of samples from 
the first batch (available at the time of assessment) illustrated that approximately 3% of 
samples were missing 10% of genotyped variants or less, and nearly 4% of samples had a 
5% missingness or less.  
Finally, the pattern of per sample missingness  compared to the distribution of autosomal 
heterozygosity was examined (Figure 2.3). Using a threshold equal to the median ± 3 × the 
interquartile range, pattern missingness vs. autosomal heterozygosity was assessed, and no 
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sample was found to be outside of the threshold range. Larger than expected heterozygosity 
can indicate the possible contamination of DNA samples.   
3.2. Sex mismatch 
To determine genetic sex, we assessed the inbreeding coefficient for the X-chromosome 
or the F coefficient ratio169, which represents the probability that a person receives genetic 
markers on the X-chromosome from a single ancestor.  
Because males have only one X-chromosome (received from the mother), the coefficient 
is defined to be 1, regardless of inbreeding. For females, the X-chromosome kinship 
coefficient is either 0 (completely outbred) or close to 0, if any degree of kinship is 
identified between the parents.  
Generally, an F coefficient value < 0.2 is considered to be genetically female, whereas a 
value > 0.8 is considered to be male. The distribution coefficients generally correlated with 
the pedigree sex (Figure 2.4), with some mismatches. autosomal allelic heterozygosity 
compared with X-chromosome (sex) heterozygosity was also assessed (Figure 2.5); results 
were similar to the F coefficient distribution and similarly included some mismatches 
between genetic vs. pedigree sex. 
3.3. Genetic outliers 
CCHC genetic observations were merged with 925 samples from the 1000 Genomes 
(1000G) project population to assess the alignment of the study participants against 
reference ancestries using the smartpca tool from the Eigensoft package. A plot of the first 
2 principal components (PCs, Figure 2.6a) suggested a few outliers with different 
ancestries compared with the rest of the samples; however, these samples did not 
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consistently separate from the rest of the samples when the third PC was considered (Figure 
2.6b and c).  
3.4. Hardy-Weinberg Equilibrium 
Determining whether genotypic frequencies are in Hardy-Weinberg Equilibrium (HWE) 
is an important step that must be performed during the quality analysis of genotyped 
variants. The HWE states that the allelic frequencies of autosomal genes in a population 
remain unchanged throughout generations in the absence of disruptive forces, such as 
assortative mating, mutation, and migration. However,  a departure from HWE is most 
likely indicative of potential genotyping errors or population stratification. Yet, given that 
the cohort under study is a recently admixed population, only extreme deviation from HWE 
was considered. A negligible number of variants were found outside of the significant 
thresholds for HWE  (< 10−6, < 10-20, <10−50, Figure 2.7). 
3.5. Duplicated samples and variants  
After analysis with Kinship-based Inference for Gwas (KING)170, 76 pairs of samples 
were found to have > 80% genetic concordance with each other. A similar number of pairs 
were also found during the pedigree reconstruction process using PRIMUS171 (Figure 2.8). 
Additionally, approximately 50K variants were also found to be duplicated.    
3.6. Quality control process 
Based on empirical observations from prior steps and the template proposed for 
performing genome-wide association studies (GWAS)172, the following quality control 
steps were performed:  
30 
 
a) removing duplicated variants and indels (insertions/deletions).  
b) removing variants with low MAF (< 1%).  
c) excluding samples with more than 5% missingness and variants with greater than 
5% missingness (among all samples).  
d) excluding samples with genetic vs. pedigree mismatch (F > 0.3 for females).  
e) removing samples that fall outside of the heterozygosity threshold or or HWE 
significance level (p-value < 1−10), and  
f) removing variants with either allelic or stand mismatch compared against the 
reference 1000G panel (this step was only completed for dataset used for imputation 
with 1000G).  
In Table 2.1, the rows represent the temporal sequence for the process. All the steps were 
completed using the PLINK package.  
4. Principal Component Analyses  
In recent years principal component analysis (PCA) has been the most widely adopted 
approach for both ancestry inference and the correction of population stratification in 
genomic studies that utilize high-density SNP genotyping data173. To calculate PCA, 
filtered data were used that were previously assessed for quality control standards (as 
discussed above) and further subseted these data  to include only common variants, with 
MAF > 5% (approximately 117,000 SNPs)The selection of common variants can improve 
ancestry inferencing because these variants are more likely to be observed in reference 
populations outside of the study.  
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Using this common variant subset, PCs were calculated using the packages GENESIS174 
(for PCAir) and PRIMUS171 (PCA). The primary difference between PCAir and PCA is 
that PCAir adjusts for pairwise kinship. The GENESIS method utilizes genomic 
observations and an efficient algorithm175 to identify a diverse subset of unrelated samples, 
which are representative of all ancestries in the data. GENESIS uses pairwise relatedness 
and ancestry divergence measurements on genotyped variants from the autosomal 
chromosomes and separates the dataset into an ancestry representative subset, u, of 
unrelated individuals from the total sample, N.  PC estimates obtained from the analysis of 
a subset u would then be used to predict PCs in the set of related individuals, R, based on 
genetic similarities175. Samples from 1000G were used as the ancestry references (N = 
2,504). 
Procedurally, PCs were first calculated using a combined set of unrelated CCHC 
individuals and reference samples. The threshold for relatedness was set to a 3rd-degree 
relatives, which equates to a first cousin or more distant relative. A slight difference in the 
number of unrelated individuals was calculated by PRIMUS vs. GENESIS (2,282 vs. 2,253) 
due to differences in their respective computational algorithms. Subsequently, PCs were 
calculated during the first phase and were then projected over the subset of related samples 
(Figure 2.9).  
A sizable majority of CCHC individuals clustered with predominantly Mexican 
populations, and smaller sets clustered with other ancestry groups (Figures 2.9). The 
parallel plot of the first 10 PCs also suggested the primacy of Mexican ancestry among the 
study participants (AMR group in Figure 2.10).  
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The analysis of explained variance by PC (Figure 2.11) suggested that a negligible 
proportion of variations in the data is captured by PCs beyond the 3rd PC.  No practical 
difference was observed between the PRIMUS-calculated PCA and PCAir (Figure 2.12); 
therefore, PRIMUS-derived PCs were selected to ensure consistency with other research 
studies using the same cohort.  
5. Imputation 
5.1. Pre-imputation quality control 
Using McCarthy group tools (well.ox.ac.uk/~wrayner/tools), genotyped variants 
underwent further quality control assessments. Steps included strand update (top strand), 
position check, and the assignment of reference/alternative allele assignments for 
genotyped PLINK files. The following categories of variants were excluded from the set:  
i) A/T and G/C SNPs if MAF > 0.4.  
ii) SNPs with differing alleles (relative to the reference genome), and  
iii) SNPs with > 0.2 allele frequency difference (compared to the reference genome). 
5.2. Imputation panels 
A cleaned dataset was loaded into the Michigan Imputation Server176 for imputation 
using a 1000G Phase 3 panel and a Trans-Omics for Precision Medicine (TOPMed) freeze 
8 panel (imputation.biodatacatalyst.nhlbi.nih.gov). The advantages of the 1000G panel 
include well-characterized reference ancestry groups, along 26 clusters and from all 
continents and wider adoption in genetic studies, which would facilitate the replication and 
meta-analysis of different studies using the same set of variants.  
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TOPMed (nhlbiwgs.org), in contrast, is a consortium of over 30 different study cohorts. 
Compared with 1000G, the latest freeze 8 reference panel was inferenced from the deep 
sequencing of 186K individuals, which represents a substantial improvement in the 
number of available variants for imputations and increased diversity of ancestry groups. 
Currently, this freeze includes 811M SNPs and 66M short indel variants. The availability 
of larger numbers of SNPs would greatly facilitate genetic studies that involve rare or 
ancestry specific variants. However, TOPMed is a work in progress and is not yet as 
widely adopted as 1000G. 
5.3. Imputation procedure 
With both 1000G and TOPMed servers, imputations were completed with the 
Minimac4177 imputation platform. The mean imputation accuracy was set to 10%. For 
genotype phasing, where each allele is assigned to its proper pair of (paternal or maternal) 
chromosomes (for haplotypic referencing), the Eagle phasing algorithm178 was utilized. 
During the TOPMed imputation run, all populations were selected as the parameters for 
ancestry reference.  
The results and the number of variants imputed with TOPMed for each chromosome are 
presented in Table 2.2. An average of approximately 92% alignment between the reference 
panel and the genotyped set was achieved. Additionally, the results from the TOPMed 




5.4. Post-imputation quality control 
Variants with rare MAF (< 1%) and poor imputation quality (< 40%) or monomorphic 
(i.e., all individuals having the same genotype at a given site) within the study population 
were excluded from this analysis. After the completion of the recommended quality control 
steps, approximately 9 million SNPs remained, which were used for subsequent analyses.  
6. Phenotypes 
BMI was selected as the measure for overall adiposity, and WHR and WC were selected 
as reliable indicators of central obesity and visceral adiposity, respectively; all three 
measures are significantly correlated with inflammatory markers and have been widely 
adopted in GWAS research on adiposity traits. For inflammation, phenotypes, including 
CRP, IL6, IL8, and fibrinogen, were included in the assessment (Table 2.3). Exploratory 
analyses of the target traits showed skewness in the distributions of inflammatory markers, 
which was suggestive of extreme values at the left tails, although a few high values were 
also observed for BMI and WHR (Figure 2.13). The data included measurements taken at 
both visits 1 and 2.  
6.1. Covariates 
For GWAS analysis, covariates including age (year), sex and BMI were considered. For 
pathway analysis, age, sex, physical exercise (binary, 150 min of moderate to viborous 
activity/week), alcohol consumption (Ounce/week), current smoking status (binary) and 
homeostatic insulin resistance (HOMA-IR, uIU/mL) were used. Covariates used for 




6.2. Inclusion/exclusion criteria 
The study population was restricted to individuals whose genetic data were available 
(3,313 out of 4,933). All participants under the age of 15 were excluded from the study 
because notable differences exist between genes that affect childhood vs. adulthood 
obesity180. Prior assessments in larger settings also suggested sexually dimorphic 
anthropometric variants in regard to central obesity181; therefore, both WHR and WC traits 
were stratified by sex. Finally, the log-transformed distributions of traits were assessed.  
For the IL-6 and IL8 phenotype, the empirical distribution suggested a proportion of 
observations with the same value (0.64 pg/dL), and this pattern was often observed with 
measurements taken before January 2010. This value is unlikely to have been the detection 
threshold for the assay because values smaller than 0.64 were identified. Whether some 
portion of the values were rounded as a standard reporting practice could not be 
determined. To minimize bias in the results, the last non-missing observation for each trait 
in each sample was selected for GWSA analysis (Table 2.4).  
6.3. Examination of phenotypic outliers 
A considerable number of extreme observations were identified at both tails (Figure 2.13, 
empirical distributions; Figure 2.14, log-transformed distributions). Although outliers 
could introduce noise or induce false-positive associations in genetic tests, aggressive 
filtration can reduce sample sizes and inversely affect power; therefore, a delicate balance 
is necessary. To address this issue, two comparative methods were utilized: 
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6.4. The minimalistic approach 
Using the minimalistic approach, both biological plausibility and empirical distributions 
(both raw and log-transformed) were used as criteria for setting outlier cut points. For 
anthropometric traits, almost all of the observations were in ranges that were biologically 
plausible, even if clinically abnormal. Therefore, only a few extreme cases that were 
considerably detached from the rest of the distributions at each tail were excluded.  
For CRP, clinical studies have shown that concentration levels above 350 (mg/L) are 
indicative of underlying severe acute inflammation182, whereas levels ranging from 10–
100 (mg/L) could either indicate active inflammation or be a high normal. Given the 
empirical distribution and clinical criteria, a few observations above 200 (mg/L) were 
excluded.  
For IL6, the upper range of measurement can be as high as 1000 (pg/dL), especially in 
individuals with underlying conditions (e.g., infection, cancer, chronic diseases). However, 
we used both empirical distribution and the reported literature to determine a cut-off point 
of 100 (pg/dL) as the threshold for outliers, as observations above this level are generally 
considered to be abnormal and are less likely to be observed in individuals without acute 
inflammation183,184.  
For IL8, levels as extreme as 10,000 (pg/dL) have been reported in severely ill patients185. 
Based on the empirical distribution and the highest ranges known for non-acute cases, the 
threshold was set to 80 (pg/dL)186,187. For all traits, extremely low measurements (observed 
in the log-transformed distributions, Figure 15) were also excluded. After the filtration of 
outliers, the remaining measurements were log-transformed and rank-normalized. 
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6.5. Hybrid approach  
Although the minimalistic approach excluded extremes, the dataset continued to include 
values that were otherwise abnormally high or low; therefore, the possibility of severe or 
acute underlying diseases being present at the time of measurement could not be excluded. 
In such scenarios, data is customarily rank-normalized to minimize the likelihood of bias 
in the results; however, this process can induce additional problems, such as the loss of 
statistical power188. Therefore, a more conservative outlier examination was deemed 
necessary, particularly for inflammatory traits.  
First, the distribution of inflammatory markers in similar Hispanic ancestry populations 
was reviewed in the literature (Table 2.5), which provided inferences for setting standard 
deviation-based cut-off points for each trait. Subsequently, the data were log-transformed, 
and the values outside of the proposed cut-off points were then set to missing. Descriptive 
distributions of the study phenotypes used during the hybrid filtration approach are 
presented in Table 2.6.  
Lastly, outliers were examined to ensure that no specific pattern could be observed. 
6.6. Selection of the phenotype set 
No discernible difference was observed for either phenotype set after the conclusion of 
the GWAS tests. Therefore, the results from the hybrid assessment process were selected 
for subsequent analyses.  
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7. Statistical Approach 
7.1. Genome-wide association test 
Generalized linear models are now the primary statistical tools used during association 
analyses in various scientific fields189, including biology. Assuming that the subjects are 
independent, the linear association between the outcome (phenotype) and predictor (SNP 
variant) can be written as 𝑀1: 𝑔(𝐸(𝑌)) = 𝑋𝛼 + 𝐺𝛽, where 𝑌 is a vector for continuous or 
binary phenotype data, 𝑔 is a link function, 𝑋 denotes confounders, and 𝐺 is the SNP 
dosage.  
However, given the study setting, in which a sizeable proportion of the individuals have 
kinship relationships with each other, a generalized linear mixed model (GLMM) would 
be more appropriate to allow for family structure adjustments, beyond the ancestry PCs 
that account for most distant relatedness and ethnic variations. Hence, a mixed model was 
implemented in the GENESIS package190 for use during GWAS tests.  
GENESIS fits linear mixed models for quantitative phenotypes and penalized-quasi 
likelihood for binary (or count) traits. In comparison with other packages that use the 
Likelihood Ratio or Wald tests 191-193, GENESIS uses the Lagrange-Multiplier (score)194 
test. A distinguishing feature of score-based tests is that only the null model must be 
specified to make statistical inference; thus, this type of model is computationally faster 
than the other two types, for which more complicated models must be fitted. 
The package uses a reduced maximum likelihood (REML) algorithm195, a special form 
of maximum likelihood estimation, in which the degrees of freedom are used to estimate 
fixed effects while calculating variance components. Compared with the general maximum 
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likelihood method, REML operates on linear combinations of observations, chosen such 
that those combinations are invariant to the values of fixed-effect parameters.  
Relatedness due to familial relationships is accounted for by including a random effect 
term with a covariance matrix proportional to the genetic relationship matrix (GRM) or 
kinship matrix 𝐾. Specifically, the GLMM assumes that the variance matrix for the 
phenotype 𝑌 has the form 𝑉1: 𝑉𝑎𝑟(𝑌) = 𝜎2𝐼 + 𝛾2𝐾, where 𝐼 is the identity matrix. In a 
single SNP analysis, the computing time was greatly reduced by estimating 𝜎2 and 𝛾2 from 
the null model 𝑀0: 𝑔(𝐸(𝑌)) = 𝑋𝛼 and then using these estimates in a score test of 𝛽 = 0 
in 𝑀1.  
For the family structure effect, the GENESIS package uses PC-Relate196. Briefly, PC-
Relate is a PC-based approach for the estimation of commonly used measures of recent 
genetic relatedness, such as kinship coefficients and identity by descent (IBD), which share 
probabilities in samples with population structures, admixture, and HWE departures.  
PC-Relate is essentially a hypothesis (model)-free approach for inferring recent kinship 
because it does not require prior estimates of individual ancestry and population-specific 
allele frequencies, IBD-sharing likelihood models, or the specification of a population 
genetic model. It uses PCs calculated from genomic data to partition genetic correlations 
among individuals into two separate groups based on the sharing of recent or more distant 
common ancestry196. 
7.2. Pleiotropy assessment  
Various pleiotropy methods have recently been proposed197 that take advantage of the 
increased availability of summary statistics from trait-specific GWAS. Most of these 
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methods offer superior statistical power compared with multivariate analysis198. Because 
the GWAS results in this study were based on score tests, the adaptive Sum of Powered 
Scores test (aSPU), which itself is essentially a score-based test, refined for multi-trait 
association testing199, was used for pleiotropy assessments.  
Briefly, suppose 𝑈 = (𝑈1 … 𝑈𝑘)
𝑇 to be the score vector for a set of k trait-SNPs to be 
tested with the H0: β = 0. The score test is: 𝑇𝑆𝑐𝑜 = 𝑈
𝑇𝑉−1𝑈, which is equivalent to an 
asymptomatic Wald test with k degrees of freedom. The popular single-variant test for 
correlated traits is the univariate minimum P  (UminP) method, which tests every single 
variant, one-by-one, and selects the minimum of their p-values200.  





201, where Uj is the element of U, and V is the (j,j) diagonal element 
of the 𝑉 = 𝐶𝑜?̂?(𝑈). However, when the number of traits increases, the test loses power. 
To address this issue, the sum of score tests was proposed202: 𝑇𝑆𝑢𝑚 = ∑ 𝑈𝑗
𝑘
𝑗=1 .  
This test may also be ineffective when the direction of effects across traits differs. One 
solution was the sum of squared score (SSU) test202:  𝑇𝑆𝑆𝑈 = 𝑈
𝑇𝑈 = ∑ 𝑈𝑗
2𝑘
𝑗=1 , which was 
later scaled to a more generalized test that can be adapted for different scenarios203:  
𝑇𝑆𝑃𝑈(𝛾) = ∑ 𝑈𝑗
𝛾𝑝
𝑗=1 , where gamma is the power parameter. Note that when the gamma 





|𝑈𝑗| = 𝑇𝑆𝑃𝑈(∞), 




 However, because these scenarios cannot be known in advance, an adaptive (aSPU) 
approach is necessary to maximize the power of a given set of gamma values; hence204: 
𝑇𝑎𝑆𝑃𝑈 = min
𝛾∈Г
𝑃𝑆𝑃𝑈(𝛾), where 𝑃𝑆𝑃∞𝑈(𝛾) is the pleiotropic p-value of the test and Γ contains 
a set of suggested gamma (i.e. 1,2,3…∞) values, of which at least one value may maximize 
the detection power. 
7.3. Fine-mapping 
Although GWAS or pleiotropy analysis can provide crucial insights into the genetic 
underpinnings of phenotypes, these analyses do not necessarily indicate causality. Due to 
linkage disequilibrium (LD) between SNPs or coverage quality of genotyping panels (SNP 
tagging)205, variants with the lowest p-values may not be phenotype-affecting SNPs.  
Fine-mapping is a statistical analysis approach that can be used to assign a causal 
probability to GWAS-inferenced variants. In this study, two complementary methods were 
utilized for fine-mapping loci with suggestive evidence for multi-trait associations after 
pleiotropic analysis.  
7.3.1. PAINTOR 
The PAINTOR (Probabilistic Annotation INTegratOR) approach takes advantage of both 
the LD structure and functional annotation. In association analysis for continuous traits, 
values are marginally regressed on each variant, and the corresponding Z-score (?̂?/𝑠𝑒(?̂?)) 
is obtained.  
Assuming that 𝑍𝑗 is the vector of the [pleiotropic] Z-score in the 𝑗
𝑡ℎ locus (1 ≤ 𝑗 ≤ 𝐿) 
of the size 𝑁𝑗 (i.e., total number of SNPs in the locus); Σ𝑗 is the corresponding SNP pairwise 
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pearson correlation coefficient for the locus 𝑗 (i.e., LD matrix), derived from a set of 
unrelated individuals with 𝐾 annotations (1 ≤ 𝑘 ≤ 𝐾) for each SNP 𝑖; 𝐴𝑖,𝑗 is a binary 
vector where 𝐴𝑖,𝑗,𝑘 = 1 if the 𝑖
𝑡ℎ variant at the 𝑗𝑡ℎ locus is part of the annotation 𝑘; 𝛾𝑘 is 
the effect size of the 𝑘𝑡ℎ annotation on the probability that a SNP is causal; 𝜆𝑖 is the vector 
of non-centrality parameter ; 𝐶𝑗is the vector of causality, where 𝐶𝑖,𝑗 = 1 if SNP 𝑖 at the 
locus 𝑗 is causal; then the prior probability of the Bayes formulation is206: 
𝑃(𝑍𝑗|𝐶𝑗; 𝜆𝑗) = 𝑁(𝑍𝑗; Σ𝑗(𝐶𝑗 ∘ 𝜆𝑗), Σ𝑗) 
𝑃(𝐶𝑗; 𝛾𝑘) =  ∏ 𝑃(𝐶𝑖𝑗; 𝛾𝑘)
𝑖
… (1) 
𝑃(𝐶𝑖𝑗; 𝛾𝑘) =  (
1
1 + exp (𝛾𝑘𝐴𝑖𝑗𝑘)
)𝐶𝑖𝑗(
1
1 + exp (−𝛾𝑘𝐴𝑖𝑗𝑘)
)1−𝐶𝑖𝑗 … (2) 
PAINTOR computes posterior probabilities of each causal configuration 𝐶𝑗 over all 
possible causal configurations 206: 𝑄𝑗(|𝑄𝑗|) =  ∑ (
𝑁𝑗 
𝑖
)𝑠𝑖=0 , where S is the potential causal 
numbers considered for each locus 𝑗. With equaitons above, the posterior probability for 
each 𝐶𝑗 is
206: 
𝑃(𝐶𝑗|𝑍𝑗; 𝛾𝑘, 𝜆) =  
𝑃(𝑍𝑗|𝐶𝑗; 𝜆𝑗)𝑃(𝐶𝑗; 𝛾𝑘)
∑ 𝑃(𝑍𝑗|𝐶𝑗; 𝜆𝑗)𝐶𝑗∈𝑄𝑗  𝑃(𝐶𝑗; 𝛾𝑘)
… (3) 
And the posterior probability for each SNPi,j
206:  
𝑃(𝐶𝑖𝑗 = 1|𝑍𝑗; 𝛾𝑘, 𝜆) =  ∑ 𝑃(𝐶|𝑍𝑗; 𝛾𝑘, 𝜆) … (4)
𝐶𝑗∈𝑄𝑗;𝐶𝑖𝑗=1
 
Because posterior probabilities are calculated independently for each locus, the package 
undertakes further mathematical steps that aggregate results across loci and use these 
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results to update likelihood parameters, particularly 𝛾𝑘 and 𝜆, which improve posterior 
probability estimates. The incorporation of functional annotation has been illustrated to 
significantly improve causal estimates in prior analyses158. 
7.3.2. FINEMAP 
Essentially, FINEMAP is a Bayesian approach that incorporates likelihood function, 
priors, likelihood estimation, and stochastic search algorithm162. Assuming a linear model 
𝑦 = 𝑋𝜆 + 𝜖, where 𝑦 is vector of mean-standardized values for a quantitative trait in n 
individuals and 𝑋 is a column-standardized SNP genotype matrix of dimension 𝑛 × 𝑚, the 
maximum likelihood estimate of the causal variants’ effects 𝜆 depends on 𝑋 and 𝑦 though 
the SNP correlation matrix. Priors for causal variants’ effect 𝜆 is calculated via 𝑝(𝜆|𝛾) =
𝑁(𝜆|0, 𝑠𝜆
2𝜎2∆𝛾), where 𝛾 is a binary vector, for which 𝛾𝑙 = 1 if 𝑙 is causal and 0 otherwise; 
𝑠𝜆
2 is assigned prior variance for causal effects in units of 𝜎2 = 1; and ∆𝛾 is a diagonal 
matrix.  
The probability of each causal configuration 𝛾 is assumed as 𝑝(𝛾) = 𝑝𝑘/(
𝑚
𝑘 ) when 
∑ 𝑙𝑚𝑙=1 = 𝑘. The marginal likelihood of 𝛾 is obtained by integrating the causal effects of 𝜆. 
The posterior probability of any causal configuration is estimated via 𝑝(𝛾|𝑦, 𝑋) =
(𝑚𝑘 )
−1
𝑝𝑘 × 𝐵𝐹(𝛾: 𝑁𝑈𝐿𝐿), where 𝐵𝐹 is the Bayesian factor and 𝑘 is the number of causal 
variant in that specific configuration.  
Finally, this approach uses the shotgun stochastic search207 to compare various causal 
configurations, with each obtained through the process discussed above, to identify those 
with the highest posterior probability. FINEMAP conducts a pre-defined round of 
iterations within the space of causal configuration. Each iteration is defined by deleting, 
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changing, or adding a causal SNP from the prior configuration, which is referred to as 
manipulative sampling from the preceding iteration.  
All evaluated configurations and their posterior probabilities are saved in a list, Г∗. The 
posterior probability that SNPs in configuration 𝛾 are causal is estimated by normalizing 
over the Г∗ list: 𝑝(𝛾|𝑦, 𝑋) = 𝑝∗(𝛾|𝑦, 𝑋)/ ∑ 𝑝∗(𝛾|𝑦, 𝑋)𝛾∈Г∗ , and for the particular SNP 𝑙𝑡ℎ 
to be causal: 𝑝(𝛾𝑙|𝑦, 𝑋) = ∑ 1(𝛾𝑙 = 1)𝛾∈Г∗  𝑝(𝛾|𝑦, 𝑋)
162. The advantages of this method 
are the minimal input requirements (i.e., Z-scores, minor allele frequencies, and SNP 
correlations) and the possibility of probing causal configurations with higher numbers of 
causal SNPs in each locus without incurring a substantial computation penalty.  
7.4. Causal pathway analysis approach 
Pleiotropy does not distinguish whether an observed association between a genetic 
variant and a phenotype involves direct (i.e., biologic) or indirect effects due to phenotypic 
correlations with the primary trait. Mediation refers to a type of conditional analysis, in 
which the total effect between the predictor and the outcome is appropriated between 
several factors that contribute to the association and relies on counterfactual principles208. 
Using this framework, the causal effects can be viewed as the difference between two 
potential phenotypic outcomes, depending on whether an individual carries the risk alleles 
or not (at the same time).  
Suppose 𝑇𝑖 denotes the presence of an effective allele, which would be equal to 1 if 
present and 0 otherwise;  𝑌𝑖(𝑡) would denote the potential phenotypic outcome under allelic 
presence status; then, the causal effect of the variant on the phenotype would be 𝑌𝑖(1) −
𝑌𝑖(0) for all values of 𝑖. However, because only one state (either 1 or 0) is observable at 
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any time for each 𝑖, the focus is typically shifted toward the estimation of the average causal 
effect by comparing two groups based on the randomized distribution of the effect allele, 
defined as 𝐸(𝑌𝑖(1) − 𝑌𝑖(0))
209.  
Assume that the causal association between a given allele and a phenotypic outcome is 
totally or partially mediated by another [correlated] factor. Let 𝑀𝑖(𝑡) denote the potential 
value of a mediator of interest for subject 𝑖 for a given allele status 𝑇𝑖 = 𝑡. Let 𝑌𝑖(𝑡, 𝑚) 
denote the potential outcome that would be observed if the allele and mediating variables 
equal 𝑡 and 𝑚, respectively.  
In practice, only one potential outcome is observable, and that outcome, 𝑌𝑖, is equal to 
𝑌𝑖(𝑇𝑖, 𝑀𝑖(𝑇𝑖)), where 𝑀𝑖(𝑇𝑖)) represents the observed value of the mediator 𝑀𝑖 . The total 
effect of the allele on the outcome can be written as 𝜏𝑖 = 𝑌𝑖(1, 𝑀𝑖(1)) − 𝑌𝑖(0, 𝑀𝑖(0)). The 
total effect can then be decomposed into the two components: the causal mediation effect210 
𝛿𝑖 = 𝑌𝑖(𝑡, 𝑀𝑖(1)) − 𝑌𝑖(𝑡, 𝑀𝑖(0)), for the effect allele status (0,1), and direct effect 𝜁𝑖 = 
𝑌𝑖(0, 𝑀𝑖(𝑡)) − 𝑌𝑖(0, 𝑀𝑖(𝑡)), for subject 𝑖 and each allele status (0,1).  
For both decomposed elements, including 𝛿𝑖 and 𝜁𝑖, because only one effect allele status 
is observable, the average causal mediation effect (ACME) and the average direct (ADE) 
could be estimated, as 𝐸𝛿𝑖 and 𝐸𝜁𝑖 , respectively. Now the total effect can be re-written as: 
𝜏 = 𝐸(𝑌𝑖(1, 𝑀𝑖(1)) − 𝑌𝑖(0, 𝑀𝑖(0)) =
1
2
∑ {𝛿(𝑡) +  𝜁𝑡=0 (𝑡)}𝑣, and under the assumption 
of no interaction, ACME and ADE sum up to the average total effect211.  
46 
 
7.4.1. Sensitivity analysis 
Causal pathway sensitivity analysis proposed for this study relies on the sequential 
ignorability212 assumption. The test implies that after adjustment for covariates, no 
unmeasured variable confounds any of: 1) variant-mediator association (i.e. ignorability of 
effect allele state)212:  𝑌𝑖(𝑡, 𝑚), 𝑀𝑖(𝑡))  ⊥⊥ 𝑇𝑖|𝑋𝑖 for all 𝑡, 𝑚 = 0,1, where 𝑋𝑖is covariate(s), 
2) allele-phenotype outcome association: 𝑌𝑖(𝑡, 𝑚)  ⊥⊥ 𝑀𝑖(𝑡))|(𝑇𝑖 = 𝑡, 𝑋𝑖) for all 𝑡, 𝑚 =
0,1, and 3) mediator-outcome relationships. The validity of the this mediation method 
largely rely on assumption 1, regardless of whether hierarchical models are fitted to the 






8. Tables and Figures 
Table 2.1 Quality control steps completed with genotyped variants prior to principal 
component analysis. 
Filter Samples Variants 
Baseline dataset 3,739 1,849,381 
Remove duplicate variants & indels  1,796,564 
Remove variants with >10% missingness  1,771,718 
Remove samples >3% missingness 3,584  
Remove one pair of duplicate samples (the pair with higher 
missingness) 
3,508  
Remove variants maf<1%  921,083 
Remove variants with >5% missingness  917,256 
Remove samples with >5% missingness 3,506  
Remove samples outside heterozygosity filter (f coefficient >0.3) 3,505  
Remove samples with pedigree vs genetic sex mismatch 3,387  
Remove variants violating hwe (p-value<1e-10)  914,301 
Remove variants with allele/strand mismatch (vs. 1000 genome panel 
variants) 
 843,850 
Remove control samples 3,313  

















Table 2.2 The number of variants imputed for each chromosome using TOPMed panel. 





1 4,889,931 7 3,575,429 
2 5,277,930 8 3,426,745 
3 4,370,489 9 2,690,807 
4 4,310,328 10 3,008,743 
5 3,980,182 11 454,157 
6 3,782,515 12 2,931,624 
13 2,183,250 19 1,393,198 
14 1,948,976 20 1,379,845 
15 1,781,331 21 810,711 
16 1,984,703 22 865,521 
17 1,774,596 X 2,388,886 
18 1,731,175 Total 60,941,072 
 
Table 2.3 List of the phenotypes selected for the study. 
 
Selected phenotype Reason for inclusion 
Body Mass index  Associated genes also linked to inflammation 114 
WAIST Circumference  A reliable indicator of visceral adiposity, and 
significantly correlated inflammation and 
cardiovascular risk factors 213 
WAIST to HiP Ratio  A reliable indicator of visceral adiposity, and 
significantly correlated inflammation and 
cardiovascular risk factors 214 
C-reactive Protein Plays a leading role between adiposity-CVD 215,216 
Interleukin-6 Associated genes significantly linked to variation 
in adiposity in Europeans 217 
Interleukin-8  Inflammatory marker significantly raised in 
hyperlipidemia and cardiovascular diseases 
context 218 





Table 2.4 Descriptive Distribution of anthropometry and inflammatory phenotypes. 
 
Table 2.5 Proposed cut-points for exclusion of phenotypic outliers under hybrid approach.  




CRP g/dl 2.7 (1.2–6.0)  Hispanics 220 ± 2.4 SD 
IL6 pg/dl 1.6 (0.8–2.8)  Hispanics 220 
± 2.8 SD IL6 pg/dl 0.5(0.5-10)  Hispanics 221 
IL6 pg/dl  0.9(0.8) Hispanics 221 
IL8 pg/dl  3.7(2.3) Hispanics 222 
± 2.6 SD 
IL8 pg/dl 4.4(3.2–5.9)  Hispanics 223 
Fibrinogen g/L  2.8(0.75) Mixed 224 
± 2.8 SD 
Fibrinogen g/L  3.6(3.4) Mixed 225 
WHR-F WC/H 
 
± 3.0 SD 
WHR-M WC/H ± 3.0 SD 
WC-M cm ± 3.0 SD 
WC-F cm ± 3.0 SD 
 




13.29 26.31 29.88 30.91 6.96 34.31 70.48 3180 
WHR-Female(wc/hip*100) 36.39 86.5 91.3 91.19 7.93 96.03 184.79 2087 
WHR-Male(wc/hip*100) 66.31 91.6 95.98 95.93 7.59 100.21 215.79 1093 
Waist-female (cm) 37 90 99.5 101.03 16.56 110 186 2088 
Waist-male (cm) 68 94 102.5 104.16 15.2 112 168 1096 
CRP (mg/L) 0.08 2 3.99 7.97 14.3 8.1 242.5 1937 
IL-6 (pg/dl) 0.01 1.4 2.68 5.6 20.97 4.91 521.38 1362 
IL-8 (pg/dl) 0.0 3.42 4.69 6.53 7.13 6.81 100.01 1499 
Fibrinogen (mg/L) 0.05 0.51 0.8 0.95 0.74 1.18 11.89 2544 
AGE(Year) 15.00 33.00 45.00 49.92 17.22 59.00 94.00 3180 
50 
 























16.16 26.30 29.86 30.76 6.53  34.25 57.21 3159 
WHR-Female(wc/hip*100) 69.89 86.54 91.30 91.17 7.08  96.00 116.39 2077 
WHR-Male(wc/hip*100) 77.87 91.70 96.01 95.94 6.40  100.22 113.58 1084 
Waist-female (cm) 62.00 90.00 99.50 100.77 15.52  109.50 158.00 2072 
Waist-male (cm) 68.30 94.00 102.50 103.95 14.62  112.00 157.00 1089 
CRP (mg/L) 0.35 2.00 3.90 6.23 6.93  7.73 50.03 1880 
IL-6 (pg/dl) 0.16 1.44 2.68 4.32 5.74  4.87 47.38 1336 
IL-8 (pg/dl) 1.10 3.42 4.67 5.67 3.58  6.65 25.56 1448 
Fibrinogen (mg/L) 0.15 0.51 0.80 0.92 0.56 1.17 4.06 2506 
AGE(Year) 15.00 33.00 45.00 49.92 17.22 59.00 94.00 3159 
51 
 










Figure 2.3 Per sample missingness vs autosomal heterozygosity. No sample was observed 
outside proposed threshold (median ± 3 × interquartile range for autosomal heterozygosity) 
which would have been indicated with black colored data points. 
 
Figure 2.4 Distribution of F ratio coefficient. Each data point is an individual. Green color 
represents female pedigree sex, and shape indicates genetic sex where round shape suggests 
ambiguous genetic sex, trigon is male and square is genetic female sex. A number of 




Figure 2.5 Sex vs autosomal heterozygosity. Each data point is an individual; color 
represents genetic sex where blue is pedigree recorde female and red is male. Results are 



















Figure 2.6 Eigensoft calculated ancestry outliers. Note that the pattern of ancestry outliers 













Figure 2.7 Hardy-Wienberg Equilibrium. A negligible number of variants were found 
outside of the significant thresholds for HWE  (< 10-6, < 10-20, <10-50). 
 
Figure 2.8 Kinship structure comparing identity by descent (IBD) parameters; IBD1 of 1 
or close indicates child-parent kinship because they share 50% of their DNA markers. 
IBD0 is defined ~1 for pair of unrelated individuals if no recent shared ancestry. IBD2 of 
1 suggest ~100% ancestry genetic concordance which can only be observed in 
monozygotic twins or duplicated samples. Approximately 76 pairs had >80% genetic 




Figure 2.9 Projection of the first three PCAir for CCHC over 1000G individuals for 
ancestry inference. Nearly all individuals cluster with American ancestry population, 
which entail Mexican and Native ancestry groups. (Note: CCHC (study group),American 
(AMR), East Asian (EAS), African (AFR), European (EUR), Southeast Asian (SAS)). 
 
Figure 2.10 Parallel plot of the first 10 PCs. Nearly all individuals cluster with American 
ancestry population, which entail Mexican and Native ancestry groups. Y-axis values were 
scaled with “uniminimax’ method with 0 set for minimum observed measure and 1 for 




Figure 2.11 Screeplot for PCs. Note that PCs beyond the 3rd do not capture significant 
variation in the data.  
 
 








Figure 2.13 Distribution of phenotypic markers using observations from visit 1 & 2. 
Skewed distributions of inflammatory traits suggest presence of some extreme measures.  
 








GWAS AND PLEIOTROPY 
A GWAS primary assessment tool used to identify thousands of genetic loci associated 
with one or multiple biologic and disease traits. In this chapter, mixed models GWAS were 
used to investigate association of SNPs with 9 anthropometric and inflammatory 
phenotypes. In the second part, the GWAS summary statistics were utilized to investigate 
pleiotropy across anthropometry and inflammatory domains. Cross-trait look-ups 
identified SNPs associated with metabolic, inflammatory and brain disease traits within or 
in close proximity to 3 genetic regions on chromosome 3, 12 and 18 with suggestions for 
pleiotropy. 
1. Background  
Since the early 2000s, GWAS have been extensively used to locate single-nucleotide 
variants associated with complex phenotypes, including body mass index (BMI)226, 
measures of central obesity227-229, and inflammation105,230. A portion of genetic variants 
that have been primarily identified in association with anthropometric traits and 
inflammation have also been noted to display functional relationships with other 
domains159,231. For instance, obesity-associated variants in the LEPR, APOC1232, GCKR, 
MC4R159, CSN1S117, FDFT1 and PCCB genes107 have also been associated with 
inflammation. Conversely, genetic loci associated with inflammatory markers233 also 
appear to be associated with variations in body weight and adiposity levels118,119.  
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Besides genetics, other clinical234, pharmacological234 and observational235 studies have 
also demonstrated synergistic associations between adiposity and inflammation. These 
overlaps may indicate that anthropometric traits, which are often used as surrogates for 
adiposity, may share certain biological pathways with the inflammatory processes that 
underpin cardiovascular diseases. Termed pleiotropic variants127, these multi-effect 
variants have been associated with multiple phenotypes107.  
Despite strong evidence for pleiotropy, existing studies have limited inferential utility 
because the majority of genetic research has been conducted in populations with European 
ancestry. This well-attested lack of diversity in genetic studies139 not only hinders the 
discovery of more variants associated with underlying functional pathways, a phenomenon 
referred to as missing heritability236, but also poses considerable problems for the 
functional characterization of known variants due to differences in allelic frequency237, 
linkage disequilibrium (LD)238, and genetic architecture among populations with divergent 
genetic ancestries from Europeans239,240.  
These genetic dissimilarities extend to phenotypic traits including inflammatory markers 
and adiposity indices. Significant discrepancies have been identified in the distributions of 
inflammatory markers across various ancestry groups, even after adjusting for differences 
in adiposity configurations142. Additionally, BMI-adjusted distributions of adipose tissues 
suggest distinct ancestry patterns241, as Hispanics, in comparison to European ancestry 
populations, tend to exhibit higher levels of visceral fat242. These observations have 
suggested that various functional pathways are likely to be affected by ancestry-specific 
pleiotropic variants. Thus, a genome-wide, systematic, and comprehensive evaluation of 
pleiotropy in the Hispanic/Latino population is needed. 
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In this study, using genetic observations obtained from CCHC, GWAS tests were 
performed to assess the associations between 3 anthropometric traits including BMI, WHR, 
and WC measurements and 4 inflammatory markers including IL-6, IL-8, fibrinogen, and 
CRP.  
During the second step, using summary statistics from the GWAS analysis, the aSPU 
method243 was employed to examine pleiotropy among the phenotypes of interest. Finally, 
bioinformatic annotation of top signals was conducted. 
2. Methods 
2.1. Study population 
CCHC is a cohort of Mexican Americans residents of Cameron county in the state of 
Texas. Elevated prevalence of cardiovascular risk factors including type 2 diabetes, 
dyslipidemia and overweight in this group indicate a population highly susceptible to 
adverse metabolic events 166.  
Out of 5,000 individuals recruited for the cohort, a sub sample of 3313 genotyped 
individuals are included in this study. Genetic measurements were completed at the 
Vanderbilt University Medical Center genotyping core facility, VANTAGE, using MEGA-
EX Array panel.  The median proportion of European ancestry in the cohort is 45.8%, 
African 11.0%, and Amerindian 42.9%.   
2.2. Covariate selection 
GWAS studies involving WHR, WC244,245, and inflammatory traits246 often incorporate 
BMI as a covariate to identify genetic effects that are independent of overall obesity. 
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Univariate regression was used to examine the associations between the phenotypes 
included in the present study. Significantly associated variables identified by univariate 
analysis were incorporated as covariates in the GWAS analysis.  
Linear regression models, both with and without adjustments for sex and age, were 
employed to determine how many ancestry principal components (PCs) were significantly 
associated with variations in phenotypic measurements and should, therefore, be used as 
covariates. Age and sex were universally employed as covariates with association tests. 
Phenotypes were log-transformed and fit into linear regression models, adjusted for age, 
sex, BMI, and the first three PCs; BMI was not used during fibrinogen and IL-8 analyses 
because no association was observed between these variables during the univariate 
analyses. These residuals were subsequently used as the outcome variables in GWAS tests 
(supplementary Figure 3.1).  
2.3. GWAS test 
Covariate-adjusted GWAS typically focuses on associations between single-nucleotide 
variants and phenotypic measures. In contrast to methods that test a small number of 
candidate regions, GWAS studies investigate a larger number of genotyped/imputed 
variants that are spread across the entire genome. Therefore, GWAS is principally a 
hypothesis free approach247. 
Residuals were used to perform GWAS testing (see chapter 2). A score-based, mixed 
linear regression model was adopted, and a pairwise kinship coefficient was incorporated 
as a random effect parameter. The kinship threshold was set to a third-degree relationship, 
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which equates to first-degree cousins. All phenotypes were treated as continuously 
measured variables.  
The tests assumed additive model of association where the SNP effect is proportional to 
the presence of risk allele. For those samples harboring two risk alleles receive higher 
scores than those who were heterozygous for the locus, and zero score is assigned if both 
non-risk increasing alleles are identified248. Because imputed SNPs constituted the 
dominant share of the variants, the two most common methods of assigning SNP score 
were the best guess genotype (posteriori) which assigns a discrete count of risk alleles 
(0,1,2), and allele dosage which is the estimated (expected) fractional counts of effect allele 
at each SNP for each individual, ranging continuously from 0 to 2. The first method is 
sensitive to imputation quality while the second approach appears to be effective and 
efficient to account for the uncertainty in the imputed genotypes249, particularly when 
expected effect sizes are small. Indeed, regression analysis of a sample ~20K SNPs with 
BMI phenotype showed a median of 8% [IQR: 3%, 21%] difference in standardized effect 
sizes using the best guess vs dosage method. Therefore, SNP dosages were used for GWAS 
tests. 
 For WC and WHR, GWAS were conducted for both sexes, separately, to account for the 
inherent sexual dimorphism of these traits181. A total of 9 GWAS were completed including 
GWAS for BMI, WHRBMI-adj in females, WHRBMI-adj in males, WCBMI-adj in females, 
WCBMI-adj in males, CRPBMI-adj, IL-6BMI-adj, IL-8 and fibrinogen. Additionally, sex-specific 
GWAS for WHR and WC were meta-analyzed, using the inverse-variance weighted 
method, to create sets of sex-combined GWAS results for both traits. 
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Statistical significance was set at a Bonferroni-corrected level [5 × 10−8] to adjust for 
multiple testing. Manhattan plots were used to visualize the GWAS results, in which the 
negative log of the p-value for each variant-phenotype association test was plotted against 
each genomic region. Established genetic loci for traits of interest were marked in the 
Manhattan plots. This step also served as a quality control step to determine whether the 
GWAS tests successfully replicated known SNPs and could, therefore, be 
methodologically validated.  
GWAS tests were performed using R package GENESIS174, while visualizations were 
completed with R package EasyStrata250. WHR and WC GWAS meta-analyses were 
performed with the METAL package251. Computations were completed on the Longleaf 
server for the University of North Carolina, Chapel Hill.  
2.4. Post-GWAS sensitivity analysis 
To assess whether the observed signals were driven by less frequent or poorly imputed 
variants, which can pose a challenge for the replicability of results, a series of filtration 
criteria were utilized including: 
• MAF<5%  
• Minor allele count <30 (MAF × N (sample size)) 
• Imputation quality <80%  




The threshold for each quality control (QC) criterion was inferenced from empirical 
distributions, as well as a review of the literature252,253. After obtaining different subsets of 
GWAS results with each filter (or combination of filters) for each trait, QQ-plots and 
genomic inflation factors (λ)250 were used to assess the type 1 (false-positive) error. An 
inflation factor (λ) value of >1.05 would be indicative of mild inflation, whereas a value 
>1.1 would indicate serious inflation based on the observed p-values, which would 
necessitate the adoption of stricter genomic-control measures.  
2.5. Pleiotropy test 
To perform an exploratory analysis of genetic correlations between phenotypes, a 
pairwise genetic distance matrix was constructed based on genetic similarities. The aSPU 
199 test was utilized to perform the multivariate assessment of genetic pleiotropy. A major 
strength of the aSPU test over other methods is that the loss in power is negligible when 
the number or portion of non-associated variants increases203, which is a distinguishing 
feature in the context of this study, in which univariate GWAS results were inferred from 
smaller sample sizes.  
Briefly, the method aggregates information across n phenotypes for a given SNP by 
taking the sum of its univariate GWAS Z-scores each raised to some power  γ, so that a 
higher γ increases the influence of strongly associated phenotypes on the score.  By 
allowing γ to take one of many competing values (1,2,…,∞), aSPU selects a maximally 
efficient scheme to detect combined phenotype effects on the entire group of phenotypes. 
A set containing trait-specific GWAS-inferred Z-scores (from all contributing 
phenotypes) was constructed. Pleiotropy analysis was performed using the JaSPU 
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(github.com/kaskarn/JaSPU) package, with the number of iterations set to 1011. This 
program relies on a Markov Chain Monte-Carlo (MCMC) 254 iterative process, which is 
applied to univariate Z-scores, estimated by inverse-variance-weighted meta-analysis to 
generate pleiotropic p-values.  
Finally, the covariance matrices for pleiotropy results were examined to ensure that no 
dimension (i.e., phenotype) exhibited considerably small or large eigenvalues; excessively-
large eigenvalues are indicative of the disproportionate contribution of a phenotype to a 
pleiotropic signal, whereas very small values indicate the opposite, and either result would 
suggest that the underlying hypothesis for pleiotropy would not hold, at least for some 
phenotypes.  
Exploratory genetic correlation analyses [prior to pleiotropy] were completed using 
GCTA package 255.  
2.6. In-depth probe of suggestive pleiotropic signals 
All variants with a pleiotropic p-value of paspu< 5 × 10
−5 were extracted from the output. 
From this output, a subset of variants with a more stringent significance level (paspu < 5 × 
10−6), which were robust to post-GWAS quality assessments and harbored clusters of 
variants with low SNP-specific (γ < 4) scores were selected. The final criterion provides a 
mechanism for grouping loci from the most to least likely to be pleiotropic.  
Among these select variants, the univariate negative log p-values from the GWAS results 
were extracted and incorporated into heatmap plots to elucidate which phenotype(s) were 
the likely drivers or contributors to the pleiotropic signals. Heatmap plots were constructed 
using gplots R package 256. 
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2.7. Functional evaluation of pleiotropic signals 
For selected loci with evidence of pleiotropy, the GWAS catalog was probed to identify 
whether any variant within the selected 1 Mbp distance on both sides of each genomic 
region and in LD with variants within the region (D`>0.5) had previously been reported in 
association with the phenotypes under study or with any other traits/diseases and how 
commonly theses variants were identified. The findings were tallied by phenotypic 
domains from all suggestive loci. GWAS catalogue (ebi.ac.uk) and NCBI 
(ldlink.nci.nih.gov/?tab=ldtrait) were used for this assessment. 
3. Results 
3.1. Descriptive statistics 
Descriptive distributions of the study population are shown in Table 3.1. The ages of the 
participants ranged from 15–94 years, with a median of 45 years. The BMI (weight (kg)/ 
height (m2)) distribution indicates that this cohort is three-quarters overweight (BMI ≥ 25), 
one-half obese (BMI ≥ 30), and at least one-quarter moderately-to-severely obese (BMI ≥ 
35).  
The median values for WHR (WC/hip (cm) × 100) and WC (cm) in women were 91.3 
and 99.5, respectively, whereas, in men, these values were 96.0 and 102.5. The difference 
between the mean and median values of inflammatory markers indicated skewed 
distributions, with the exception of fibrinogen, with a mean value of 0.92 g/L, which is 




3.2. GWAS results 
Phenotypic residuals extracted from linear regression analyses were used as dependent 
variables in mixed model GWAS tests. A total of 9,262,347 variants, covering 
chromosomes 1-22, passed imputation quality control and were, therefore, included in the 
GWAS tests. Manhattan plots of the GWAS results for BMI, WCBMI-adj in women, WCBMI-
adj in men, sex combined WCBMI-adj, WHRBMI-adj in women, WHRBMI-adj in men, CRPBMI-adj, 
IL6BMI-adj, IL8, and fibrinogen are shown in supplementary Figures (3.2a–j) respectively, 
where dots represent variants, x-axes demonstrate genomic region [by chromosome 
number and base pair position] and y-axes demonstrate negative log of GWAS p-value of 
each SNP.  
In the sex-combined meta-analyses for the WHRBMI-adj GWAS (Figure 3.1), two GWAS-
significant signals (P<5.0 x 10-8) were observed for WHRBMI-adj, on chromosomes 6 and 8. 
The signal on chromosome 8 corresponds to a locus previously associated with WHR, 
whereas the signal on chromosome 6 has not been previously reported in the literature 
(Table 3.2, Figure 3.1). No GWAS-significant variants were observed in either known loci 
(denoted by the blue color) or other regions for any other trait. 
3.3. Sensitivity analyses 
Variants beyond the significance threshold set for the study (i.e., p-value < 5 × 10−6) for 
each trait (supplementary Table 3.1) were examined to assess whether the top signals were 
driven by less frequent or poorly imputed SNPs, which may affect the replicability (i.e., 
generalizability of observed signals). Supplementary Table 3.1 shows the counts of 
significant variants remaining after the application of each (or the combination of) QC 
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criteria for MAF, MAC, imputation score, and effective sample size. Few signals were 
likely driven by less common variants (i.e., MAF < 5%), no poorly imputed SNPs were 
identified in the results. Application of MAC & MAF resulted in near maximal removal of 
less common variants compared to baseline GWAS results (i.e., non-filtered GWAS) and 
therefore adopted as the post-GWAS filtration criteria. 
Comparisons of inflation factors for each subset illustrated that no substantial inflation 
affected the association tests, as all λ values ranged from 0.99–1.03, well below the 1.05 
threshold level (supplementary Table 3.2). Therefore, no genomic control application was 
deemed necessary. However, few Q-Q plots suggested deflation, particularly at the left tail, 
where fewer highly significant variants were observed than expected, particularly for those 
GWAS subsets that excluded less common variants (i.e., MAC>30 and MAF>%5 filtered 
GWAS subsets) (Figure 3.3a–d).  
3.4. Pleiotropy results 
The preliminary examination of genetic correlations between phenotypes, inferred from 
GWAS summary results, illustrated that both inflammation and anthropometry-associated 
variants clustered with their respective phenotypic domains (supplementary Figure 3.4). 
However, fibrinogen was a notable exception, which correlated more closely with WCBMI-
adj in men than with inflammatory markers.  
A Manhattan plot of the pleiotropy results included no significant GWAS variants, either 
in regions known for associations with any of the study traits (denoted by a blue color) or 
novel loci (Figure 3.2). However, suggestive signals were identified in several 
chromosomes, including 1, 3, 12, 18, and 19, which merited further evaluation. The 
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absence of very small or large eigenvalues in the covariation matrix made it unlikely that 
the observed pleiotropic outcomes were driven by any solitary trait (supplementary Table 
3.3).  
The in-depth interrogation of the locus on chromosome 3 revealed that IL-6, BMI, and 
WC in men were the primary drivers of the pleiotropic signal (Figure 3.3a). For the locus 
on chromosome 12, GWAS results from CRP, BMI, fibrinogen, WHR, and WC in women 
were contributors to the signal (Figure 3.3b). However, for the locus on chromosome 18, 
the pleiotropic association appeared to be disproportionately driven by WHR in women, 
with fibrinogen playing a minor part (Figure 3.3c). Of the three loci, the region on 
chromosome 12 appeared to be the most promising for pleiotropic potentiality. The signals 
on chromosome 1 and 19 only contained solitary variants for each and did not include 
clusters of associated SNPs. 
Finally, the online library of GWAS catalog was probed to explore whether any of the 
variants in the selected regions had previously been reported for any phenotype or are in 
LD (D`>0.5) with variants identified for those phenotypes. In two of three regions, on 
chromosomes 12 and 18, several variants were reported in association with energy intake 
or WHR, although they were not identified often (Table 3.3).  
In the target region on chromosome 3 (bp chr3:4120729-4262732, ±1Mbp on either 
directions), a significant number of variants were observed in association with brain 
function and diseases, lipid levels, inflammation, and metabolite levels; few were identified 
for body weight and type 2 diabetes. For the locus on chromosome 12 (bp chr12:44476332-
44621041, ±1Mbp on either directions), SNPs linked to variations in anthropometric traits 
(WHR), inflammatory diseases, and gut microbiome were more frequently reported. For 
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the locus on chromosome 18 (bp chr18:61577041-61588083, ±1Mbp on either directions), 
variants associated with blood pressure, energy intake, allergies, autoimmune conditions, 
and cancer were identified (Table 3.3).  
4. Discussion  
The study results provided suggestive evidence for at least 3 pleiotropic signals 
associated with both adiposity and inflammation which indicated a considerable degree of 
genetic overlap.  
Two regions on chromosomes 6 and 8 exceeded the GWAS significance level for sex-
combined meta-analyzed WHR results (Table 3.2, Figure 3.1). Although the signal on 
chromosome 8 has previously been reported, the signal on chromosome 6 has not been 
previously recorded in the GWAS libraries. GWAS-significant SNPs in the novel locus 
occur in the region between LRFN2 and LOC101929555. Variants in LRFN2 have been 
reported in association with BMI 257,258, type 2 diabetes 259, lipid profiles 260, cognitive 
abilities 261, and WHR 262. LOC101929555 has not yet been functionally characterized.  
A number of loci that have been widely reported and mapped for associations with 
anthropometric and inflammatory traits, including the SNPs in IL6 on chromosome 7 (for 
IL-6) 263 or FTO on chromosome 16 (for BMI) 264, did not exceed the GWAS threshold 
level. Although larger studies have ascertained the transferability of a sizeable proportion 
of phenotype-associated common variants across various ancestries 265, including 
anthropometric 266,267 and inflammation-associated variants 267, important ethnic 
differences were also noted 268-270, even in known genomic regions 271.  
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Although these observed patterns could suggest an ancestry-specific association pattern, 
caution must be exercised because differences in the LD structure 239, study sample sizes 
238, and dissimilarities in variant coverage (SNP tagging 272) can all induce differences in 
the GWAS signals across various study settings or ethnicities 271.  
Although no variants exceeded the GWAS significance level in the pleiotropy analysis, 
suggestive signals were identified on chromosomes 3, 12, and 18 (Figure 3.2 & Figure 
3.3a-c). Multiple phenotypes appeared to contribute to the loci on chromosomes 3 and 12, 
whereas the signal on chromosome 18 was primarily driven by WHR in women.  
Additional variants were also identified: one on chromosome 1 (rs952499) overlapping 
gene ABCA4, and another on chromosome 19 (rs669560) overlapping ZNF708, with strong 
pleiotropy p-values (< 5 × 10−7). However, in both instances, the signals were driven by 
solitary SNPs that were not in tight [or loose] LD with any other variants that exhibited 
significant pleiotropy p-values. 
A review of the GWAS library to identify suggestive pleiotropic loci showed that an 
extensive number of variants were already reported for associations with a range of 
metabolic and inflammatory functions. For the probed region on chromosome 3, a sizeable 
number of SNPs were shown to be associated with brain function and diseases, liver 
function, triglyceride, inflammation, type 2 diabetes and body weight(Table 3.3).  
Similarly, for the suggestive region on chromosome 12, many variants were associated 
with anthropometric indices, and inflammatory diseases. The third probed locus on 
chromosome 18 also contained variants associated with inflammation, WHR and blood 
pressure indices.  
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There few methodological considerations. The Q-Q plots for the IL-6 and IL-8 GWAS 
results suggested deflation at the left tails (supplementary Figure 3.3a-d). Factors including 
the overcorrection of GWAS test statistics in polygenic phenotypes (such as cytokines) 273 
and adjustments for pairwise kinship in mixed-model GWAS tests 274 could potentially 
induce deflation. However, the severity of deflation increased when less common variants 
(MAF < 5% and MAC < 30) were excluded, which indicated that deflations were likely 
induced by reduced power (supplementary Figure 3.3c and 3.3d).  
The age distribution of the participants suggested a middle-aged cohort that was slightly 
older than the general Hispanic population (Table 3.1). The prevalence of obesity was 
higher than the national average level for the Hispanic population, as reported by the 
Centers for Disease Control and Prevention (CDC) for the 2017–2018 period 275 (45% vs. 
>75% in this study). However, the distributions of WHR and WC suggested that central 
obesity, likely caused by an accumulation of visceral fat, represents the prevailing form of 
adiposity, as over three-quarters of both men and women had measures above their 
respective threshold levels [WHR > 85 in women and WHR > 90 in men 276] for obesity. 
These results, together with the presence of higher levels of inflammatory markers, 
presented an opportunity for pleiotropy assessment due to the increased statistical power 
despite a modest study sample size.  
Fibrinogen was the only inflammation marker with lower distribution (mean = 0.92 g/L) 
compared with the average range reported by other studies (1.5–2.5 g/L) 277,278. However, 
this marker is known to exhibit considerable within-sample variability, even in healthy 
individuals 279. Additionally, fibrinogen measures were significantly correlated with WHR, 
WC, and interleukin levels, which suggested that the observed values may be a function of 
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the caliber of the assay rather than the reduced distribution of this marker in this study 
group. 
In conclusion, the overlap in SNP associations with similar phenotypic domains for all 
three regions underscores the complexity and interrelatedness of traits that are otherwise 
viewed as independent and highlights the need for a greater focus on pleiotropic SNPs that 
can provide novel insights into the underlying mechanisms that drive these traits. The high 
prevalence of adiposity and inflammation in this cohort highlithed the need for pleiotropy 







5. Tables and Figures  
 
Table 3.1. Distributions of inflammatory and anthropometric phenotypes and age among 
Cameron County Hispanic Cohort (CCHC) subjects. 
*reporting unit: Waist/Hip(cm)×100 
 
 





Rsid Nearest Genes Z-score P-value 
6 40810472 rs12524956 LRFN2,LOC101929555 -5.61543 1.96E-08 
6 40810278 rs12524922 LRFN2,LOC101929555 -5.49004 4.02E-08 
8 72499840 rs202053146 EYA1, MSC 5.54286 2.98E-08 
8 72524159 rs1424869 EYA1, MSC 5.52103 3.37E-08 
8 72488774 rs972738 EYA1, MSC 5.53007 3.20E-08 
8 72484519 rs59354633 EYA1, MSC 5.52962 3.21E-08 
8 72492249 rs35727416 EYA1, MSC 5.46058 4.75E-08 
8 72473729 rs10504510 EYA1, MSC 5.4889 4.04E-08 






Phenotype (Unit) Min. 1st Qu. Median Mean SD 3rd Qu. Max. N 
BMI (kg/m
2
) 16.16 26.30 29.86 30.76 6.53 34.25 57.21 3159 
Waist-female (cm) 62.00 90.00 99.50 100.77 15.52 109.50 158.00 2072 
Waist-male (cm) 68.30 94.00 102.50 103.95 14.62 112.00 157.00 1089 
WHR-Female* 69.89 86.54 91.30 91.17 7.08 96.00 116.39 2077 
WHR-Male* 77.87 91.70 96.01 95.94 6.40 100.22 113.58 1084 
CRP (mg/L) 0.35 2.00 3.90 6.23 6.93 7.73 50.03 1880 
IL-6 (pg/dL) 0.16 1.44 2.68 4.32 5.74 4.87 47.38 1336 
IL-8 (pg/dL) 1.10 3.42 4.67 5.67 3.58 6.65 25.56 1448 
Fibrinogen (g/L) 0.15 0.51 0.80 0.92 0.56 1.17 4.06 2506 
Age(year) 15.00 33.00 45.00 49.92 17.22 59.00 94.00 3161 
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Table 3.3. Functional probe of three loci on chromosome 3, 12 and 18 with suggestion 





Within ± 1 Mbp of the region and 
in LD (D`>0.5) with variants 
Within ± 1 Mbp of the 
region and in LD (D`>0.5) 
with variants 
Within ± 1 Mbp of the 
region and in LD (D`>0.5) 
with variants 
Brain function or diseases WHR Allergy, inflammatory, 
autoimmune diseases 
Blood proteins/metabolites Height Anthropometric traits 
(WHR) 
Inflammatory diseases/markers Idiopathic scoliosis Energy intake 
Weight  Immune response cancer 
Type 2 diabetes Gut microbiome Blood pressure 
Metabolite levels  
 
 
Lipid levels (triglyceride)    
Liver function (AST)    


















Figure 3.2. Pleiotropy Manhattan plot. Dots represent genomic variants; x-axis indicates  
chromosome number and base pair position for single nucleotide polymorphisms (SNPs) 
and y-axis demonstrate pleiotropy p-value for each variant. Blue color denotes known loci 













Figure 3.3a-c Heatplots of variants with trait-specific GWAS pvalues of <5 × 10−5  
located within the three loci with suggestive evidence for pleiotropy; rows show variants 
and columns display traits. Row clusters represent euclidean distances between variants, 
and column clusters are based on similarity of trait-specific pvalues. Color transition (red 
to yellow) demonstrates change in trait-specific negative log GWAS pvalue for each 




6. Appendices  
 
Supplementary Figure 3.1. Distributions of phenotypic residuals used as depedent 
variables for GWAS tests; residuals were extracted from linear regression of log-















Supplementary Figures 3.2a-i: 
a) BMI Manhattan plot 
 
b) WC-Female Manhattan plot (Adjusted for BMI) 
 
 






d) WHR-Female Manhattan plot (Adjusted for BMI) 
 
 
e) WHR-Male Manhattan plot (Adjusted for BMI) 
 
 






g) Interleukin 6 Manhattan plot (Adjusted for BMI) 
 
h) Interleukin 8 Manhattan plot 
 








Supplementary Figures 3.3a-d. Q-Q plots for IL6 and IL8 GWAS. Note the deflation 
with the left tails  which suggest fewer highly significant variants were observed than 
expected, particularly for GWAS sets with reduced number of variants after exclusion 
of less common variants (i.e.,  minor allele frequency (MAF<%5) & minor allele count 









Supplementary Figures 3.4. Genetic correlation between anthropometry and 
inflammatory phenotypes. All phenotypes except IL8, fibrinogen (FIB) and BMI were 
adjusted for BMI, age and sex. Blue color in the heatplot represents negative and red a 
positive pairwise correlation, while color intensity demonstrates degree of pairwise 





















FINE-MAPPING PLEIOTROPIC SIGNALS 
In this chapter, the results of fine-mapping analysis to distinguish the set of variants with 
high posterior causal probability is presented. Three genomic loci on chromosome 3, 12 
and 18 with suggestion for genetic pleiotropy between adiposity and inflammation traits 
were probed. The locus on chromosome 12 likely harbors two independent signals. The 
functional evaluation showed the majority of fine-mapped variants were  SNPs with 
regulatory features associated with several tissues including inflammation-related cells; 
several variants also exhibited regulatory features associated with dipocytes. Results 
underscored potential contribution of regulatory variants in pleiotropy. 
1. Background 
Both  GWAS and pleiotropy studies have provided essential, initial evidence linking 
genetic variants with biologic traits or diseases. However, GWAS and, by extension, 
pleiotropy assessments, which primarily rely on summary statistics obtained from GWAS 
studies, cannot reveal the functional consequence of significant variations.  
GWAS-identified signals are typically represented by a ‘lead’ SNP, which has the 
strongest (i.e., lowest) p-value in the suspected region. This lead variant may not directly 
affect phenotypic expression but, rather, may be a proxy for a ‘true’ causal variant due to 
LD, which induces strong correlations between SNPs. Overlap or proximity with a coding 
region does not necessarily imply causality280. Further complicating the picture, multiple 
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causal and apparently independent variants within a single region can act through joint 
allelic effects on the same haplotype125.  
The biological interpretations of associations between likely causal variants are highly 
dependent on the genomic region in which the variants are located. Over 90% of the GWAS 
variants are in non-coding locus and do not directly affect messenger RNAs (mRNA)281 
transcription. The functional characteristics of these variants can vary greatly when 
operating under different cell-tissue environments282.  
Such genetic architecture complexities create challenges when attempting to functionally 
interpret GWAS and pleiotropy results. Localized analyses of risk-inducing loci must be 
performed with considerations for both allelic structures and functional annotations.  
The fine-mapping approach assigns a statistical causality probability to candidate 
variants located within the GWAS-identified regions283. In other words, this technique is 
used to filter GWAS-identified variants and distinguish SNPs that are most likely to be 
causal in each genomic region.  
Recently, a number of fine-mapping tools have been developed that utilize iterative 
algorithms to perform causal variation identification, including Markov Chain Monte Carlo 
(MCMC)284, exhaustive125 and stochastic searches285. Most of these tools assume the 
presence of a single causal variant for a given region286. However, this assumption may not 
reflect true biological reality, particularly when examining complex traits, such as adiposity 
and inflammation. Additionally, many fine-mapping packages lack rigorous statistical 
framework to incorporate tissue or cell-specific functionality286,287, which could impact 
predictive accuracy.  
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Thus, two complementary methods, PAINTOR206 and FINEMAP162, were used to 
perform the fine-mapping of adiposity–inflammation pleiotropy-identified regions from 
CCHC. Although FINEMAP is unable to account for functionality, this program uses an 
efficient algorithm that accommodates the identification of multiple causal variants, with 
no substantial computational cost162. After they were identified, the fine-mapped 
prioritized variants were subjected to functional assessments to determine biologic effect 
potentials. 
2. Methods  
2.1. Genome-wide pleiotropy summary statistics 
The dataset consisted of pleiotropy summary statistics for approximately 6 million SNPs. 
Pleiotropy statistics reflect the outcomes of univariate GWAS and pleiotropy assessments 
performed during a prior round.  
In brief, using genomic measurements from N = 3,313 participants from the CCHC study, 
a mixed-model, univariate GWAS were conducted, including anthropometric traits  (BMI, 
WHRBMI-adj, and WCBMI-adj) and inflammation markers (CRPBMI-adj, fibrinogen, IL-6BMI-adj 
and IL8; WHRBMI-adj and WCBMI-adj-GWAS were completed in males and females 
separately.  
Pleiotropy test was subsequently performed using the trait-specific GWAS summary 
statistics. Pleitropy results were converted from newer genome build GRCh38 to older 
GRCh37 for compatibility with fine-mapping packages. 
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2.2. Statistical framework 
A traditional approach used to refine association signals is conditional analysis, a 
stepwise process that conditions on the variants with the lowest p-values in association 
tests until no additional SNPs are identified that achieve the pre-determined p-value 
threshold. Although this approach can be informative regarding the potential number of 
signal sources for a specific locus, it does not deliver probabilistic measures of causality 
for variants.  
Bayesian framework has been increasing being adopted as a way to overcome this 
problem288.  However, a Bayesian approach requires both genotypic and phenotypic inputs, 
which become impractical when the sample size or number of variants increases. 
Therefore, fine-mapping methods have been extended to use only the summary statistics 
from genetic tests, together with SNP correlations obtained from reference panels125.  
PAINTOR represents a fine-mapping method that uses the LD structure and Z-scores 
from either univariate GWAS or pleiotropy results289. A distinguishing feature of this 
approach is that it leverages functional annotations of individual variants to estimate causal 
posterior probabilities. This approach is also robust when multiple, distinct causal variants 
appear to underlie functionality and in the context of heterogeneous effect sizes.  
In addition to PAINTOR, the FINEMAP package162 was utilized. Pleiotropy suggests 
functional overlap, interrelatedness, and complexity in the underlying mechanisms, which 
can all increase the possibility that multiple causal variants can be found in a given region. 
Given the high density of tested variants, the incorporation of functional annotations with 
a fine-mapping probe will exponentially increase the computational costs.  
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PAINTOR is only efficient for the probing of a maximum of 3 causal variants for variant-
dense regions. In contrast, FINEMAP package uses a Shotgun Stochastic Search (SSS) 
algorithm207 to explore various causal configurations by concentrating its efforts on 
configurations with non-negligible probabilities162. FINEMAP computes probabilities 
using summary statistics obtained from GWAS (or pleiotropy Z-scores) and pairwise LD 
estimates to facilitate the probing of an increased number of causal variants without 
computational penalty. Both packages were used complementarily to maximize the set of 
variants identified with high posterior causality probabilities.  
2.3. Defining fine-mapping loci 
From the pleiotropy summary statistics, a subset of variants with a pleiotropic 
significance level of Paspu< 5  10
−6 was subtracted. Next, the variants were further 
subdivided into independent groups based on their chromosome and base pair numbers. In 
each locus, variants were ranked by significance level, and the top SNP with the lowest 
Paspu value was selected to serve as the index for the region.  
All variants within 500 Kbps in both directions of the index were extracted from the 
pleiotropy summary statistics. For each SNP, the reference SNP cluster ID (rsid) number, 
chromosome, base pair (bp) number, pleiotropy Z-score, Paspu-value, and effective and 
alternative alleles were extracted. For the estimation of SNP pleiotropic effect sizes and 
standard errors, the following formulas were utilized:  
𝛽 =
𝑧








where 𝛽 is the effect size, 𝑧 is the Z-score, 𝑝 is the allele frequency, and 𝑛 is the sample 
size for the variants.  
2.4. Linkage disequilibrium estimation 
Pairwise Spearman’s rank correlation coefficients were estimated using the subset of 
unrelated individuals in the CCHC, in which each calculated value could vary between 
[1,−1] for any given pair. For LD calculations, LDStore2 package290 was utilized, which 
uses the binary BGEN file format291, rather than the variant call format (VCF)292, and is 
computationally more efficient than similar platforms.  
2.5. Functional annotation  
Annotation libraries included:  
a) enhancer elements from Functional Annotation of the Mammalian Genome project 
(FANTOM5)293,  
b) various functional annotations from ENCylopedia of Dna Elements (ENCODE) 
project294 including transcription factors295, enhancers296 and promoters297,  
c) protein coding elements from gene-ENCODE (GENCODE)298,  
d) super enhancers299,  
e) DNase I hypersensitive sites (DHSs)281 regulatory elements.  
The functional annotation of selected regions was performed with the PAINTOR package 
in two steps.  
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During the first step, all annotations associated with the functionality of the liver, brain, 
blood, muscle, adipose tissues, and exon variants were used to annotate variants in the 
target loci. 
Because a proportion of annotations could overlap and induce multicollinearity, 
correlation matrices were created using annotation scores from the annotated loci, such that 
each value in the matrices represented a pairwise correlation between a pair of annotations. 
One pair of annotations, with correlation values > 0.2, was set to missing.  
The removal process was repeated several times until the remaining set of annotations 
was roughly uncorrelated (i.e., all pairwise correlations were below the established 
threshold). The remaining annotation set was then utilized for the target regions annotation. 
2.6. Fine-mapping process 
Fine-mapping analysis was completed using PAINTOR at each locus, separately, 
incorporating LD scores and annotations files and assuming up to 3 causal variants per 
locus. With FINEMAP, analyses were performed by assuming up to 10 causal variants per 
region. All variants with posterior causality probabilities > 0.5 were extracted from the 
outcomes of both packages to maximize the number of likely causal variants identified at 
each locus. These subsets were used for the downstream functional assessments.  
2.7. Functional evaluation  
Several bioinformatic platforms were utilized  
i) Ensemble Variant Effect Predictor (VEP), from Ensemble300 (grch37.ensembl.org/), 
was used to determine the effect of each likely causal variant on genes, transcripts, protein 
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sequences, and regulatory regions. VEP was also used to perform the Combined 
Annotation-Dependent Depletion (CADD) coding score estimation301; this score is widely 
used to measure variant deleteriousness. A negative log-transformed CADD score > 10 
suggests a high probability of an effect on protein coding. 
ii) Enhanced Accuracy in Predicting the Functional Consequences of Non-coding and 
Coding SNV (FATHMM-XF)302 is a method for predicting point mutations within the 
human genome the probable effect of the predicted point mutation on protein coding: a 
score > 0.5 (of a maximum of 1) indicates a likely coding effect, whereas a score > 0.9 
indicates a highly pathogenic or protein-altering mutation. 
iii) Haploreg is a tool for evaluating the annotation of a noncoding genome at variants on 
haplotype blocks, such as candidate regulatory SNPs at disease-associated loci303. This 
annotation tools is use to assess the effects of SNPs on regulatory motifs and expression 
Quantitative Trait Loci (eQTL), which are genomic regions associated with expression 
levels of messenger RNA (mRNA). 
iv) ClinVar is a PubMed-supported and publicly available tool for assessing links 
between variants and human phenotypes. 
2.8. Independence of signals 
Lastly, pairwise Spearman’s rank correlation coefficients were calculated between likely 
causal variants in each region. A cut-off value of R2 < 0.1 was used to determine 
independence, as correlation values below this threshold suggest that the pair of variants 
likely represent different functional signals.  
93 
 
2.9. Visualization of pleiotropic signals. 
To perform a more localized visualization of those loci with evidence for pleiotropy, 
locuszoom plots304 were employed. For each locus, the variant with the lowest paspu was 
selected as the index, and all variants within a distance of 1 megabase pairs (Mbp) were 
plotted on either side of the index SNP.  
LD between the index SNP and all other variants within the probed region were 
calculated using the set of unrelated individuals from the CCHC (i.e., individuals with a 
third-degree kinship relationship or more distantly related). The populations used for the 
genotyping reference were Hispanics from the Population Architecture using Genomics 
and Epidemiology (PAGE II) cohort (pagestudy.org). The fine-mapped variants with high 
causal posterior probabilities were marked with distinguishing shape. 
3. Results 
The analysis of pleiotropy results indicated three regions on chromosomes 3, 12, and 18 
with potential for pleiotropic associations. Out of 7,236 variants assessed, a total of 22 
variants showed a posterior probability of > 0.5 for all three regions combined. In addition 
to 9 variants suggest by PAINTOR, 13 SNPs were distinguished by FINEMAP. The results 
in Tables 4.1a–c show the variants with the highest posterior probability of causality in 
each locus.  
For the locus on chromosome 3 (bp range: 3,653,147–4,650,039), a total of 9 SNPs were 
identified with posterior probability values > 0.5 (out of 3,234 SNPs assessed, Figure 4.1). 
As noted, all variants are intronic, nonsense-mediated mRNA decay (NMD) SNPs. Both 
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the FATHMM-FX and negative-log CADD scores were considerably below their 
respective threshold values of 0.5 and 10, which suggested low probabilities that these 
SNPs were protein-altering variants.  
However, several variants showed either extensive regulatory annotations with 
immunity, skin, pancreas, spleen, gastrointestinal, and lung tissues or were in tight LD (i.e., 
R2 > 0.8) with SNPs featuring regulatory annotations associated with those tissues (Table 
4.1a). One SNP, rs60505812, featured a regulatory annotation associated with adiposity 
tissue, although it was not in high LD with any other regulatory variant.  
All variants overlapped with the gene encoding sulfatase-modifying factor 1 (SUMF1)-
NMD transcript on the reserve strand (Ensemble ID: ENSG00000144455). Estimates from 
pairwise LD analysis (Supplementary Table 4.1, Figure 4.1) indicated that likely one causal 
SNP exists in this region because the pairwise correlation estimates were generally above 
the threshold level of R2 > 0.1.  
For the locus on chromosome 12 (bp range: 43,981,459–44,980,751), 8 variants had 
posterior probabilities > 0.5 (out of 1,501 SNPs examined, Table 4.1b, Figure 4.2). Similar 
to results for chromosome 3, most SNPs featured low coding scores and were intronic and 
NMD, except rs440389 and rs277221, which are intergenic with no significant regulatory 
features associated with any tissue. The remaining 6 SNPs have variable regulatory 
annotations associated with immunity, skeletal muscle, adipose, blood, vessels, lung, and 
pancreas tissues.  
The most notable variant from this list is rs73093474, which features multiple regulatory 
annotations with adipose, immunity, brain, and pancreas tissues, and is also located in a 
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region replete with regulatory SNPs. The two variants at the top of the list overlapped with 
the gene encoding interleukin 1 receptor-associated kinase 4 (IRAK4) 
(ENSG00000198001); these two variants may represent a second, independent signal 
within the region given their negligible pairwise LD with the other likely causal variants 
in the region (Supplementary Table 4.2, Figure 4.2). The remaining fine-mapped SNPs 
overlapped with the gene encoding transmembrane 117 (TMEM117) 
(ENSG00000139173).  
Finally, for the locus on chromosome 18 (bp range: 61,079,369–62,075,853), 5 variants 
exhibited posterior probability values > 0.5 (out of 1,301 SNPs evaluated). The second and 
third variants on this list are intergenic, whereas the remaining variants are intronic and 
downstream/upstream to regulatory SNPs. The last two variants (rs28483202 and 
rs631815) did not exhibit any regulatory annotations with the bioinformatic tools that were 
used.  
The first and fourth variants overlapped with the genes encoding serpin family B 
members 10 (SERPINB10) and 2 (SERPINB2). The last variant on the list, rs631815, 
overlapped with both the genes encoding histocompatibility minor serpin domain-
containing (HMSD) and the AC009802.1 region, which has not yet been functionally 
characterized.  
All variants appeared to point to the same signal, as the pairwise LDs were above the 




In this study, summary statistics from pleiotropy analysis, information on pairwise 
correlations between SNPs inferenced from a set of unrelated individuals in the study, and 
functional annotations for regulatory and coding variants from highly referenced libraries, 
including ENCODE294 and FANTOM5293, were incorporated to determine the genomic 
loci with the highest probability of exerting a causal role on genetic pleiotropy between 
adiposity and inflammation.  
Functional assessments were intended to expand upon the statistical findings to narrow 
the results to those SNPs that may have the most biological relevance. Because adiposity 
and inflammation are complex traits305,306 that are highly polygenic307-310, a higher 
probability exists for the identification of multiple, independent causal signals, even within 
relatively small regions311. Therefore, the fine-mapping analysis using PAINTOR, which 
allows the incorporation of functionality, was complemented with FINEMAP outcomes, 
both to expand on the credible set of causal variants for each signal and to increase the 
probability of identifying additional signals in each fine-mapped region, assuming that 
such signals exist.  
Based on summary statistics from the pleiotropy analysis, three loci on chromosomes 3, 
12, and 18 were identified based on suggestive evidence for contributions to pleiotropy 
between adiposity and inflammatory traits in a Hispanic population. After the application 
of the statistical approach, 22 variants showed posterior causality probabilities greater than 
50% from the 7,236 variants assessed across all 3 regions.  
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The index SNPs identified in each region were associated with the most significant p-
values for pleiotropy, including rs200671707 on chromosome 3, rs60939199 on 
chromosome 12, and rs4609952 on chromosome 18; however, these three SNPs did not 
have high posterior causality probability values. The fine-mapping algorithm may not have 
been able to differentiate causal variants when the underlying structure is correlated, and 
several significant variants exist.  
Highly significant variants from the pleiotropy analysis results may also represent 
proxies of ‘true’ causal SNPs that are not presented in the dataset and, therefore, the 
observed associations are biased toward the tagged (observed) SNPs312. Evidence exists to 
support a role played by topologically associated domains (TADS), which refer to distant 
loci that interact with each other313 and are believed to have significant impacts on the 
functional genome314. Therefore the GWAS and pleiotropy signals used for this analysis 
may have resided in different genomic regions that interacted with the observed locus.  
Finally, this lack of causality associated with highly significant SNPs may indicate the 
presence of multiple, independent signals; however, the pairwise LD estimates 
(Supplementary Table 4.1-3) suggest that only the fine-mapped region on chromosome 12 
may harbor an additional independent signal if any such signal exists.  
In the fine-mapped region on chromosome 3, a total of 9 variants had high causal 
probability values. Two SNPs, including rs60505812 and rs10514654, are notable. The 
first variant has regulatory features associated with adipose tissue, whereas the second 
variant exhibited regulatory annotations associated with immunity, skin, and intestinal 
tissues. A relatively elevated coding score (CADD = 6.8) suggested that the mutation in 
rs60505812 may potentially affect mRNA transcription, although the score remains below 
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the cut-off value of 10 that denotes mutational significance315. Therefore, in the context of 
the protein-coding process, it is less likely to be a high-impact SNP.  
All suggestive causal variants in this region overlapped with SUMF1, which encodes 
sulfatase-modifying factor 1 enzyme, a protein that catalyzes glycosaminoglycans, 
sulfolipids, and steroid sulfates316. Defects in this gene are known to cause multiple 
sulfatase deficiency316, a lysosomal storage disease that contributes to the deterioration of 
tissues in the nervous system, resulting in motor dysfunction, seizures, and developmental 
delays317. However, variants in this gene have also been linked to inflammation in chronic 
obstructive pulmonary disease (COPD)318. Furthermore, steroid sulfates play functional 
roles in energy homeostasis and inflammation319.  
The analysis of the target region on chromosome 12 showed that 8 variants had high 
causality probability values. Pairwise LD estimates (Table 4.2b) indicated two different 
signals. The two variants at the top of the list overlapped with IRAK4, whereas the 
remaining variants were associated with TMEM117. Although the first variant is intergenic, 
its only regulatory feature was associated with trophoblast tissue, whereas the second 
variant (rs4251527) was linked with regulatory activities in blood and immune cells.  
IRAK4 encodes a protein kinase, which is essential during the innate immune response 
to Toll-like receptors (TLRs), and its deficiency increases the susceptibility to infections320. 
Studies of obese mice showed that the overexpression of TLRs in enlarged adipose tissue 
might play an important role in obesity-induced inflammation321.  
Two variants in the same region (on chromosome 12) that overlap with TMEM117, 
including rs73093474 and rs10506239, merit further interrogation. The first variant has 
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regulatory features associated with an extensive number of tissues, including adipose, lung, 
brain, lung, and pancreas. The second variant shows regulatory annotation with brain tissue 
(Table 4.1b). TMEM117 encodes transmembrane protein 117 and has been associated with 
endoplasmic reticulum-stress (ER-stress) and mitochondria-mediated cell death322.  
Lastly, after probing the locus of interest on chromosome 18, a total of 5 variants showed 
high causality probability values. The first variant (rs6567401) overlaps with SERPINB10, 
which encodes a protein that controls the regulation of protease functions during 
hematopoiesis (blood production) and has been associated with allergic 
inflammation323,324. The second variant (rs28483202) is intronic for SERPINB2, which 
encodes plasminogen activator inhibitor 2 (PAI2), a protein known to play a role in the 
manipulation of immunity325 and is upregulated during allergic responses326. The third 
variant (rs631815) is upstream of HMSD, which is primarily expressed in cells of myeloid 
lineage327. The remaining two variants are intergenic, although the closest functional gene 
is SERPINB2.  
Generally, all but a few of the identified variants with high causality probability values 
across all three regions were intronic and NMD SNPs. NMD variants are considered to be 
regulatory, quality control variants that reduce gene expression errors by eliminating 
mRNA transcripts that contain premature termination codons (PTCs)328.  
Growing evidence suggests that variations and tissue-specific differences in NMDs can 
alter the underlying pathologies of genetic diseases329-331. Notably, interactions between 
NMDs and protein-coding variants have been linked to an increased risk of developing 
obesity and type 2 diabetes, as reported in one recent trans-ancestry cohort332. The clinical 
study of a patient with the early onset of severe obesity was associated with an NMD 
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alteration affecting proopiomelanocortin333, which is involved in a wide range of activities, 
including body weight regulation.  
Overwhelming (>90%) portion of the GWAS variants were discovered in noncoding 
genomic regions281. The results from this study underscore the significance of these 
regulatory variants and their effects on pathophysiologic processes upstream of physiologic 















5. Tables and Figures 
Table 4.1a Characteristics of variants with high posterior causal probability in the target 

































































































































































































































































































*PP= posterior probability, **NMD= Non-sense mediated decay, $PC= protein coding. 
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Table 4.1b Characteristics of variants with high posterior causal probability in the target 




































































































































































































































































Table 4.1c Characteristics of variants with high posterior causal probability in the target 
region on chromosome 18 (base pair range: 61,079,369–62,075,853). 







































































































































































Figure 4.1 Regional zoomplot of the suspect pleiotropic locus on chromosome 3. The blue 
colored rotated square in the middle represents index variant while strait squares show fine-
mapped prioritized variant with high posterior causal probabilities (>50%). The Rsid label 
shows the variant with regulatory feature associated with adipose tissue. Colors show 
degree of linkage diequilibrium (LD) with lead (i.e., index) variant in the region. Blue lines 
demonstrate recombination rate inferences from Population Architecture using Genomics 
and Epidemiology (PAGE II) Hispanic population. The horizontal bar under x-axis show 
genes overlapping or close to target region. The variant highlighted here is Non-sense 
mediated decay (NMD) variant for sulfatase modifying factor 1 (SUMF1) gene on the 











Figure 4.2. Regional zoomplot of the suspect pleiotropic locus on chromosome 12. The 
blue colored rotated square in the middle represents index variant while strait squares show 
fine-mapped prioritized variant with high posterior causal probabilities (>50%). The Rsid 
label shows the variant with regulatory feature associated with adipose tissue. The 
horizontal bar under x-axis show genes overlapping or close to target region. The variant 
















Figure 4.3. Regional zoomplot of the suspect pleiotropic locus on chromosome 18. The 
blue colored rotated square in the middle represents index variant while strait squares show 
fine-mapped prioritized variant with high posterior causal probabilities (>50%). The Rsid 
label shows the variant with regulatory feature associated with adipose tissue. The 
horizontal bar under x-axis show genes overlapping or close to target region. Fine-mapping 
prioritized variants mostly overlap with serpin family B members 10 (SERPINB10), 













6. Appendices  
Supplementary Table 4.1. Pairwise linkage disequilbrium (LD) among variants with high 
posterior causal probability in the target region on chromosome 3. LD can range from R2≈0 
[no LD] to >0.99 [very tight LD]. Values indicate variants belong to the same signal [using 













































































rs2600116 1 0.46 0.34 0.76 0.09 0.34 0.39 0.09 0.69 
rs35441937 0.46 1 0.81 0.32 0.20 0.76 0.05 0.21 0.26 
rs2874822 0.34 0.81 1 0.45 0.19 0.64 0.02 0.20 0.18 
rs10510288 0.76 0.32 0.45 1 0.09 0.26 0.29 0.09 0.56 
rs6808934 0.09 0.20 0.19 0.09 1 0.1911 0.20 0.90 0.11 
rs60505812 0.34 0.76 0.64 0.26 0.19 1 0.10 0.20 0.38 
rs952644 0.39 0.05 0.02 0.29 0.20 0.10 1 0.22 0.56 
rs10514654 0.09 0.21 0.20 0.087 0.90 0.20 0.22 1 0.11 















Supplementary Table 4.2. Pairwise linkage disequilbrium (LD) among variants with high 
posterior causal probability in the target region on chromosome 12. This locus may harbor 





































































rs440389 1.00 0.20 0.15 0.00 0.01 0.00 0.00 0.00 
rs4251527 0.20 1.00 0.08 0.02 0.02 0.02 0.02 0.01 
rs277221 0.15 0.08 1.00 0.01 0.01 0.01 0.00 0.01 
rs6099549
1 
0.00 0.02 0.01 1.00 0.01 1.00 0.93 0.88 
rs1118241
9 
0.01 0.02 0.01 0.01 1.00 0.01 0.01 0.01 
rs7309347
4 
0.00 0.02 0.01 1.00 0.01 1.00 0.93 0.88 
rs1050623
9 
0.00 0.02 0.00 0.93 0.01 0.93 1.00 0.83 
rs7309480
3 
0.00 0.01 0.01 0.88 0.01 0.88 0.83 1.00 
 
 
Supplementary Table 4.3. Pairwise linkage disequilbrium (LD) among variants with high 
posterior causal probability in the target region on chromosome 18. Values indicate 
variants belong to the same signal [using the R2>0.1 cutpoint]. 
 rs6567401 rs1243064 rs2689416 rs28483202 rs631815 
rs6567401 1.00 0.08 0.22 0.22 0.09 
rs1243064 0.08 1.00 0.34 0.73 0.82 
rs2689416 0.22 0.34 1.00 0.29 0.32 
rs28483202 0.22 0.73 0.29 1.00 0.73 








CAUSAL MEDIATION PATHWAY ANALYSIS 
In this chapter, the results from causal mediation analysis are presented. Based on 
univariate regression analysis, tighter LD, more significant pleiotropic association and 
functional annotation of likely causal variants in 3 loci with evidence for pleiotropic 
associations with adiposity and inflammation, two variants including rs60505812 on 
chromosome 3 and rs73093474 on chromosome 12were selected for in-depth causal 
mediation analysis to distinguish variants with direct (biologic) from indirect (mediated) 
pleiotropic effects. Results suggested rs60505812 may have direct and biologic association 
with both adiposity and inflammation traits. The other variant, rs73093474, exhibit both 
biologic and mediated pleiotropic effect on inflammation (via adiposity).  
1. Background  
Although GWAS have identified thousands of genetic variants associated with 
phenotypic traits126, a variety of methodological issues281,334-338 have made understanding 
the impacts of these findings in a biological context somewhat challenging339-341. The 
difficulty identifying causal variants288 and pathways that mediate genetic effects342 have 
been the two key barriers to the meaningful interpretation of genetic studies because only 
a very small fraction of identified variants are causal311.  
Despite the increased availability of fine-mapping tools for performing the localized 
probing of genomic regions206,285,286, which has greatly contributed to pinpointing likely 
causal variants, the functional follow-up necessary to determine the underpinning 
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mechanisms that connect these causal variants with phenotypic expression lags 
considerably behind343.  
This gap between genetic association studies and the identification of the related 
biological effects is an important issue, particularly when characterizing multi-potent 
variants339. The added complexity of studying these prevalent344 but less well-characterized 
‘pleiotropic’ variants127 is due to the existence of several models of associations345 that 
each implies different types of functional effects.  
As mentioned previously, based on the concept of “biologic” pleiotropy, a genomic locus 
that is independently associated with several phenotypes would suggest that the genetic 
effect is transmitted through a common pathway that is upstream of all associated 
phenotypes127; however, pleiotropic effects can also be transmitted indirectly due to 
relationships between the outcome phenotype and a “mediating” phenotype127. Elucidating 
these complexities could provide novel biological insights to better understand the 
biological pathways that underpin genotype-phenotype associations346, as well as disease 
traits127, creating opportunities for improved clinical classification and drug repurposing.  
In this study, a causal mediation pathway analysis211 of likely causal pleiotropic variants 
was performed based on evidence of an association between adiposity and inflammation. 
Mediation analysis provides a framework for distinguishing biologic from mediated 
pleiotropy and for quantifying the proportion of total genetic effects on outcome 
phenotypes347. This method was previously utilized to dissect the direct and indirect genetic 
associations between SNPs and chronic obstructive disease (COPD)348, metabolic 
syndromes349, mineral density350, and bladder cancer351.  
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The aims of these analyses were to describe the associations between fine-mapped 
variants identified on chromosomes 3, 12, and 18 with anthropometry and inflammation-
related phenotypes and distinguish whether the likely causal variants act directly (i.e., 
irrespective of any hypothesized mediator) or whether the association is predominately due 
to correlations, with particular attention paid to the prevailing understanding of causal 
inflammation and adiposity pathways352,353. To achieve these aims, a set of phenotyped and 
genotyped subjects from the CCHC were examined.  
2. Methods 
2.1. Candidate variant set 
A set of variants with posterior causal probability values > 0.5, located at three separate 
loci on chromosomes 3, 12, and 18, were considered for the causal mediation analysis. 
Variants were identified through a fine-mapping analysis performed on loci associated with 
suggestive evidence for pleiotropy between anthropometry traits, including BMI, WHR, 
and WC, and inflammation-related phenotypes CRP, fibrinogen, IL-6 and IL-8.  
Pleiotropy assessments were completed using GWAS summary statistics during prior 
steps, based on genomic measurements obtained from the participants in the CCHC study. 
Additionally, the index variants for each locus, which exhibited the lowest pleiotropic p-
values and were used to configure the fine-mapping target regions, were also included in 
the set.  
There was a total of  25 variants likely causal variants across all 3 regions. SNP allelic 
dosage for these selected variants were extracted from variant calling format (VCF)292 files. 
Allele dosage is the estimated (expected) fractional and continuous counts of effect allele 
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at each SNP for each individual, ranging continuously from 0 to 2, where a value of 2 for 
a given variant indicated that the subject harbors both phenotype-increasing alleles, 
whereas a value of 0 implies the complete absence of the risk allele.  
2.2. Phenotypes  
The last non-missing phenotypic recorded observations for BMI, WHR, WC, CRP, IL-
6, and IL-8 were extracted for all CCHC individuals whose genetic measurements were 
used in the univariate GWAS and pleiotropy assessments analyzing the association 
between anthropometry and inflammation. GWAS analyses similarly incorporated last 
non-missing phenotypic recorded observation for each trait, as well as corresponding 
covariates’ values for age and sex. Details on phenotype data collection methods were 
presented in prior steps.    
2.3. Covariate selection 
A review of prior studies showed that several factors are likely to play significant roles 
in obesity/adiposity and inflammation. In addition to age and sex354-356, variables such as 
alcohol consumption and smoking357,358, physical activity359,360, hypertension361, lipid 
profile362,363, and insulin sensitivity364 have been reported.  
It is arguable that few of the enlisted factors, including lipid levels and blood pressure, 
could act as the mediators of the association between adiposity and inflammatory 
outcomes365,366 and not as the confounders. In the case of insulin resistance, although 
studies have indicated causal associations, with adiposity serving as an outcome 
predictor367,368, other assessments have indicated that the accumulation of visceral adipose 
tissue could be a consequence of increased insulin resistance rather than a cause20,369.  
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Therefore, in this study, the following covariates were incorporated into the mediation 
models: homeostatic model assessment of insulin resistance (HOMA-IR), age (years), sex 
(binary), alcohol consumption (oz/week), moderate to vigorous level of physical activity 
(binary), current smoking status (binary), and ancestry principal components (to adjust for 
population stratification). The alcohol level was obtained by tallying the average number 
of alcoholic beverages consumed within a week, which was multiplied by 0.6 (or 0.48 for 
wine, based on the National Institute of Alcohol Abuse and Alcoholism (niaaa.nih.gov) 
formulation for the level of alcohol content in different beverages). A moderate to vigorous 
level of physical activity was defined as 150 minutes of sweat-inducing activities in a week. 
The values for covariates were taken from the same exam where primary phenotypes 
were taken. 
2.4. Statistical analysis 
The list of fine-mapped-prioritized SNPs and index variants in the 3 target regions with 
evidence for pleiotropy and their SNP dosage values were tested for univariate associations 
with the study phenotypes (BMI, WC, WHR, CRP, IL-6, and IL-8) using linear regression 
assuming an additive genetic effect.  
Pairwise correlations were calculated between the index SNPs and variants with high 
posterior causality probability values (with PLINK package370) to assess whether the fine-
mapped variants are in LD with their respective index SNPs. Variants with the strongest 
significant associations with phenotypes, in the tightest LD with the index SNPs, and 
sharing functional features associated with adiposity- and inflammation-related tissues 
were subsequently selected for causal mediation analysis.  
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Analyses were limited to samples with non-missing observations for outcome 
phenotypes. An exploratory analysis of the phenotypes showed the skewed distributions of 
inflammatory markers; therefore, inflammation phenotypes were log-transformed 
(supplementary Figure 6.1) because mediation analysis assumes the normal distribution of 
outcomes. Some covariates, including physical activity, alcohol consumption, and smoking 
status, were characterized by considerable missingness. Because mediation analysis only 
uses complete cases, missing covariates were imputed using the predictive mean matching 
(PMM)371 method. Subsequent mediation analyses were conducted with both an imputed 
dataset (assuming missingness at random) and a reduced set that only included empirically 
complete cases.  
Directed acyclic graphs (DAGs) were used to conceptualize the biologic pathways of 
associations (Supplementary Figure 6.2). Causal mediation analysis requires that the causal 
model (i.e., the likely temporal sequence of phenotypes) be pre-specified. Causal models 
were based on the prevailing knowledge of adiposity and inflammation associations (causal 
directions) to determine the mediator and outcome phenotypes from each mediation 
analysis.  
2.5. Causal mediation pathway analysis 
Under the biologic pleiotropy model, a likely causal variant is associated with multiple 
phenotypes through distinct pathways (Supplementary Figure 5.3a). Therefore, the 
directional association between the SNP and the outcome phenotype should be significant 
(outside of the 95% error levels), once the association has been adjusted for the mediator 
(phenotype) and the covariate effects; a lack of significant associations may suggest 
mediated pleiotropy (Supplementary Figure 5.3b).  
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For this study, analyses were performed using the causal inference approach to mediation 
analysis209, which allows for the assessment of whether an SNP has a direct effect on the 
phenotype of interest or whether the SNP only acts through a secondary (correlated) 
phenotype, in a sequential manner. Distinguishing the pleiotropic operational mode assists 
in the identification of the biological pathways through which a genomic variant affects 
multiple phenotypes.  
The R package Mediation372 was used for analysis, which conducts a three-step process. 
The total effect between an SNP and an outcome phenotype is assumed to be the sum of 
the average causal mediation effects (ACMEs) and the average causal direct effect (ADE). 
The first step includes estimating the distribution of the mediator phenotype as a function 
of the SNP, adjusted for ancestry genetics (e.g., anthropometry ~ genotype + PCs). The 
next step involves estimating the distribution of the outcome phenotype as a function of 
the mediator phenotype, genotype, and covariates (e.g., inflammation marker ~ mediator + 
genotype + PCs + covariates). The final step combines the fitted models in the mediation 
equation, providing estimates and p-values for the direct (e.g., inflammation ~ SNP) and 
indirect (via adiposity) associations.  
Mediation analysis involved the stepwise selection of covariates during the second step. 
The initial formulation (Model 1) included no covariates except ancestry PCs (e.g., 
inflammation marker ~ genotype + mediator + PCs). In subsequent models, age and sex 
(Model 2), alcohol and physical activity (Model 3), smoking status (Model 4), and insulin 
resistance (Model 5) were progressively added to assess the confounding effects of 
covariates on the observed associations. Because no significant differences were observed 
between the different adjusted models, only the final adjusted model was included in this 
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report. No meaningful difference was observed between the results inferenced from the 
imputed dataset and those based on the empirical observations. Therefore, models using 
the multiple-imputation set were presented in the results section, and the results from the 
empirical set can be found in the supplementary materials.  
The number of simulations was set to 1,000, and models were calculated with robust 
standard errors. 
2.6. Sensitivity analysis  
The empirical distributions of the covariates showed the presence of extreme 
observations. Comparative analyses were conducted both with and without outliers to 
assess whether the outcomes would differ.  
For causal mediation analysis, the proposed sensitivity test in the Mediation R package 
was used. This test relies on sequential ignorability212, which implies that after accounting 
for an observed confounder, no unmeasured variable may confound any of the following: 
1) genotype-mediator association, 2) genotype-outcome phenotype association, and 3) 
mediator-outcome association.  
The package passes the results from mediation analysis to medsens function. The 
functions choses as the sensitivity parameter the correlation ρ between the residuals of the 
mediator and outcome regressions. If there exist unmeasured confounder which affect 
either the mediator or the outcome, it is expected that the sequential ignorability 
assumption is violated and ρ is no longer zero. The sensitivity analysis is conducted by 
varying the value of ρ and examining how the estimated ADE and/or ACME changes. 
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The number of simulations used for the sensitivity test was set at 100, and correlation 
parameter ρ increment was set at 0.1. 
3. Results 
The exploratory analysis of covariates (Table 5.1) showed elevated distribution of insulin 
resistance [median =2.9 µIU/mL, interquartile range (IQR): 1.7, 4.8], a low proportion of 
individuals reporting moderate to vigorous physical activity (approximately 24% of 
participants), and current smokers being the majority of the cohort (55%). The empirical 
distribution of insulin resistance values showed the presence of a few extreme measures 
(Figure 5.1). The distributions of anthropometric measures indicated a high level of obesity 
(>75% with BMI > 30 and WHR > 88) and high levels of inflammation markers (IL-6 
median =2.7pg/dL, IQR:1.4, 4.8).  
The set of variants with a high posterior probability of causality, including their 
respective index variants, were fit into a linear regression with phenotypes as the outcome. 
The results of the univariate analysis and pairwise LD-score with the lead pleiotropic 
(index) variant for each region (Table 5.2) showed inconsistent patterns of associations 
across phenotypes. In the target region on chromosome 3, only 5 out 10 variants were 
associated with BMI, WC and WHR, 4 with CRP, 3 with IL-6, 2 with IL-8, and none with 
fibrinogen, including the results from index SNP. Only 2 variants in the locus, rs605058102 
and rs10514654, were significantly associated with 5 out of 6 phenotypes.  
For the target region on chromosome 12, 5 of 9 variants were significantly associated 
with BMI, WC and CRP, 6 with WHR, 1 with IL-6, 2 with fibrinogen, and none with IL-
8, including the results from the index SNP. However, 5 of 9 variants (rs60939199, 
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rs60995491, rs73093474, rs10506239, and rs73094803) appeared to be associated with 
multiple phenotypes, including BMI, WC, WHR, and CRP. For the target region on 
chromosome 18, the results did not show any significant associations between phenotypes 
and likely causal pleiotropic variants, except for the index SNP (rs4609952), which was 
significantly associated with WHR (Table 5.2). 
Based on the significant associations with multiple phenotypes identified in the 
univariate regressions (Table 5.2), two variants were selected for in-depth causal mediation 
pathway analysis due to tighter LD with their respective index SNPs, lower pleiotropic p-
values (Paspu), and adipose tissue regulatory features (Table 5.1a-b, prior chapter): 
rs60505812, on chromosome 3 and rs73093474 on chromosome 12.  
To distinguish biological pleiotropy from mediated pleiotropy, causal mediation analyses 
were performed. Using DAGs, the regression results, and existing biological knowledge, 
separate but methodologically identical models were used to assess the total effects 
between the likely causal variants and the phenotypes of interest (Supplementary Figure 
5.4).  
For rs60505812 on chromosome 3, BMI was assumed to be the mediating phenotype, 
and IL-6 was chosen as the outcome. The selection of associated phenotypes was guided 
by univariate GWAS p-values. For this variant, no meaningful mediated effect was 
observed [estimate = 0.01 (pg/dL) per risk allele, 95% confidence interval (95% CI): −0.01, 
0.04; Table 5.3], but the direct effect was significant (estimate = 0.13 (pg/dL) per risk 
allele, 95% CI: 0.05, 0.22) after adjusting for age, sex, the first 2 PCs, alcohol consumption, 
physical activity, current smoking status, and insulin resistance level.  
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For the variant rs73093474 on chromosome 12, WHR was the mediator, and CRP was 
chosen as the outcome phenotype. Evidence supported both a mediated effect (estimate = 
−0.02 (mg/L) per risk allele, 95% CI: −0.04, −0.00) and a direct effect between the SNP 
and CRP (estimate = −0.16 (mg/L) per risk allele, 95% CI: −0.25, −0.06). This result 
implies that the variant exhibits both biologic and mediated (via WHR) pleiotropy. These 
results suggested that these two variants contributed to inflammation, independently of 
adiposity.  
The sensitivity analysis for unmeasured confounders (Figure 6.3) showed that 
unmeasured cofounders were unlikely to unduly confound direct SNP-outcome-phenotype 
associations for both variants, as the estimates were outside of the 95% CI for sensitivity 
parameters. Finally, mediation analyses were performed, excluding samples that had 
extremely high insulin resistance values. No tangible difference was observed; therefore, 
no data points were excluded from this report.  
4. Discussion  
Pleiotropy assessments performed during prior steps identified loci with suggestive 
evidence for multi-phenotype associations among CCHC participants. The functional 
evaluation of likely causal variants, identified through fine-mapping in the prior steps, 
revealed that the majority were nonsense-mediated (NMD) regulatory SNPs, underscoring 
their potential for pleiotropic effects, particularly in the context of adiposity and 
inflammation.  
However, fine-mapping analysis is restricted to the assignment of causal probability 
based on observed associations and functional annotations. Mediation analysis is an 
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approach that can be utilized to model causal associations between variants with a high 
probability of causality and phenotypic outcomes373. The characterization of pleiotropy 
associations facilitates biological interpretations. 
A total of 25 SNPs of likely causal variants, residing in three different regions, with 
evidence of inflammation-adiposity pleiotropy effects, were considered for mediation 
analysis. This set included three 3 index SNPs (i.e., the variants with the most significant 
pleiotropic p-values in each target locus) and 22 variants that demonstrated high probability 
of causality values during the fine-mapping analysis. LD analyses suggested that the 
examined variants consisted of 4 distinct signals, two of which were located on 
chromosome 12.  
Based on the consistency of associations across multiple phenotypes, adiposity tissue 
regulatory features, and tight LD with respective index SNPs, two variants, including 
rs60505812 on chromosome 3 and rs73093474 on chromosome 12, merited in-depth 
examination. None of the SNPs in the third region on chromosome 18 were associated with 
any of the traits under the study.  
Mediation analysis indicated that rs60505812 was independently associated with both 
IL-6 and BMI, which are surrogates of inflammation and adiposity, respectively, even after 
adjusting for age, sex, physical activity level, alcohol consumption, and current smoking 
status (Table 6.3), which is consistent with biologic pleiotropy. However, no indirect 
association was identified between the SNP and IL-6 [via BMI]; therefore, the model failed 
to provide evidence for mediated pleiotropy.  
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As indicated by functional analyses using bioinformatic tools in prior steps, rs60505812 
is an NMD variant. NMDs, in general, play important roles in the reduction of gene 
expression error by eliminating mRNAs that contain premature stop codons328. This variant 
is located in an intronic region of the sulfatase modifying factor 1 (SUMF1) gene, which 
is known to encode a similarly named enzyme that catalyzes steroid sulfates316. Although 
no direct association between SUMF1 and metabolic traits has previously been reported, 
variants in this gene have been suggested to be associated with inflammation318. 
Additionally, steroid sulfates play a functional role in energy homeostasis and 
inflammation319.  
The functional assessment of rs60505812 with Haploreg demonstrated an annotation 
with  histone H3 lysine 4 trimethylated (H3K4me3)374 in fetal adipose cell nuclei. 
H3K4me3 promotes gene expression by altering the accessibility of genes to initiate 
mRNA transcription 375. Whether this regulatory association and concurrent synergistic 
phenotypic variation [with fat uptake and increased pro-inflammatory activities] is 
promoted by common pathways at molecular, cellular or tissue levels require further 
assessments. However, regulatory annotation with fetal nuclei would suggest functional 
association with a wider range of metabolic processes, and therefore involving sub-cellular 
‘foundational’ pathways. 
For the variant rs73093474, on chromosome 12, mediation analysis indicated both a 
direct association with CRP (Table 6.3) and an indirect association (via WHR) in the 
covariate-adjusted models, which demonstrated concurrent biologic and mediated 
pleiotropy. In contrast to rs60505812, this variant has a regulatory annotation with the 
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mono-methylated H3K4me1-Enhancer in adipose cell nucleus, in addition to skeletal 
muscle and brain tissues.  
H3K4me1 is the primary modification used to predict whether an SNP is a potential 
enhancer (booster) of the gene expression376. Therefore, the associated regulatory effect of 
rs73093474 [or the signal it represents] may be biologically more specific than rs60505812, 
and less likely to involve multipotent pathways that underpin a greater range of phenotypic 
traits. Caution must be exercised because a concrete biological inference necessitates both 
the replication of genetic associations in larger samples and  experimental assessment.  
This SNP is also an NMD variant, intronic to transmembrane 117 (TMEM117), which 
encodes a similarly named protein. This gene has been associated with endoplasmic 
reticulum stress (ER stress) and mitochondria-mediated apoptotic cell death322. Obesity-
induced ER stress has been shown to induce inflammation in adipose tissue377.  
In conclusion, mediation analysis showed that the observed pleiotropic associations in 
two of three target regions are potentially biologic associations, in which the SNP affects 
a common pathway upstream of both inflammation- and adiposity-related phenotypes. 
However, evidence for mediated pleiotropy was also identified for rs73093474, which 









5. Tables and Figures 
Table 5.1. Distributions of the phenotypes and covariates in Cameron County Hispanic 
Cohort (CCHC) among participants with non-missing values for either C-reactive Protein 
(CRP) or interleukin (IL)-6.  
 
Variable (unit) Median [IQR] Sample Size 
Age (year) 47.0[34.0, 60.0] 2247 
Female, N(%) 1492(66) 2247 
IL6 (pg/dL) 2.7[1.4, 4.8] 1316 
CRP (mg/L) 3.9 [2.0, 7.7] 1860 
BMI (kg/height^2) 30.1[26.6, 34.3] 2237 
Waist Circumference (cm) 100.7 [92.5, 110.5] 2247 
WHR (Waist/Height x 100) 92.9[88.0, 97.9] 2245 
Alcohol (Oz/week) 0.0 [0.0, 0.6] 1196 
Moderate to vigorous physical activity, N(%) 252(23.9) 1054 
Current smoker, N(%) 578(55.0) 1050 
Homa-IR* (uIU/mL) 2.9[1.7, 4.8] 2123 


















Table 5.2. Univariate regression results with genetic variants as the outcomes and 















rs200671707 1.02E-06   2.25 2.86 2.82 1.70 0.28 3.07 2.45 
rs35441937 3.28E-01 0.10 0.96 0.52 0.52 -1.15 0.37 -0.57 0.26 0.68 
rs10510288 6.61E-03 0.24 0.99 2.14 1.98 1.15 1.64 -0.30 2.57 2.48 
rs6808934 9.34E-02 0.23 0.99 1.14 1.18 1.59 1.24 -0.79 1.86 1.36 
rs2874822 1.35E-01 0.10 0.96 -0.62 -0.75 -0.57 -0.44 -0.62 -0.62 -0.57 
rs60505812 1.28E-06 0.86 0.98 2.73 2.42 2.65 2.34 0.59 3.02 2.59 
rs952644 9.20E-03 0.19 0.92 2.10 1.68 1.39 1.75 -0.19 2.46 2.49 
rs2600116 9.48E-02 0.21 0.95 0.33 0.25 1.67 0.19 0.17 0.80 0.02 
rs10514654 1.89E-06 0.86 0.95 2.75 2.60 2.96 2.20 0.11 2.83 2.73 













rs60939199 1.56E-06   -2.50 -2.79 -1.25 -0.60 -0.87 -2.62 -3.28 
rs277221 1.33E-03 0.00 0.08 0.33 0.16 -0.48 0.56 -1.58 2.89 0.20 
rs440389 1.63E-01 0.02 0.49 -0.53 0.60 -1.95 0.04 -1.28 1.54 0.26 
rs4251527 3.87E-03 0.00 0.07 -0.68 -0.93 0.99 -0.68 2.01 -1.53 -0.16 
rs60995491 2.81E-06 0.87 0.94 -2.49 -2.85 -0.33 -0.79 -0.56 -3.32 -3.53 
rs11182419 6.56E-01 0.00 1.00 -0.60 0.26 -0.71 1.83 2.34 -0.67 -0.83 
rs73093474 2.81E-06 0.87 0.94 -2.50 -2.86 -0.33 -0.78 -0.56 -3.32 -3.53 
rs10506239 3.35E-06 0.93 0.99 -2.42 -2.84 -1.16 -0.42 -0.57 -2.87 -3.36 













rs4609952 2.67E-05   0.73 0.02 -0.20 -1.14 0.31 2.35 -0.13 
rs1243064 1.03E-02 0.21 0.97 -0.21 0.63 -0.50 0.54 -0.99 -0.81 -0.39 
rs2689416 6.65E-03 0.30 0.99 0.25 0.18 0.05 -0.77 -0.12 1.31 0.03 
rs28483202 4.48E-04 0.88 0.99 1.06 0.34 0.18 -1.40 0.38 1.87 0.01 
rs6567401 4.40E-02 0.27 0.99 0.60 0.78 -0.26 -1.15 -0.32 1.53 0.41 
rs631815 9.91E-03 0.32 1.00 0.75 0.23 0.45 -0.29 -0.47 1.06 0.21 
 
*R-squared and d` are measures of pairwise linkage disequilibrium (LD) with index SNP in locus 
[highlighted with light gray]. Variants in tighter LD with their respective index single nucleotide variants 
(SNV), having significant pleiotropy p-value (Paspu), significant association with multiple phenotypes and 
regulatory annotation features associated with adipose tissue were selected for in-depth causal mediation 








Table 5.3. Causal mediation analysis for rs60505812 and rs73093474.  
Estimate/variant  rs60505812 rs73093474 
Adjusted Model Adjusted Model 
Estimate 95% CI Estimate 95% CI 
Mediated Effect (ACME)* 0.01 (-0.01, 0.04) -0.02 (-0.04, -0.00) 
Direct Effect (ADE)** 0.13 (0.05, 0.22) -0.16 (-0.25, -0.06) 
Total Effect (TE) 0.14 (0.06, 0.23) -0.18 (-0.27, -0.08) 
Proportion Mediated 0.07 (-0.11, 0.29) 0.12 (0.01, 0.32) 
*ACME=average causal mediated effect. For the variant rs60505812, this pertains to the statistical 
association between the SNP and the outcome phenotype (IL6), mediated through BMI. For the variant 
rs73093474, the ACME indicates the association between the SNP and the outcome phenotype (CRP), 
mediated through WHR.  
**ADE=average direct effect. For the variant rs60505812, this pertains to direct association between the 
SNP and the outcome phenotype (IL6), after adjusting for the mediator (BMI). For the variant rs73093474, 
this indicates the direct association between the SNP and CRP after accounting for the mediator effect 






















Figure 5.1. Sensitivity analysis of observed average mediation effect and average direct 
effect for variants rs60505812 (lower row) and rs73093474 (top row). The 95% 
confidence interval for average mediation effect with rs60505812 includes 0 value for 
sensitivity parameter ρ but the confidence interval for average direct effect does not. For 
rs73093474, both direct and mediated effects’ confidence intervals do not contain 0 


















Supplementary Figure 5.2. Conceptual directed acyclic graph (DAG) used as the 
framework for causal mediation analysis. This approach is based on general mediation 





Supplementary Figure 5.3. Biologic pleiotropy indicates direct association with 
multiple phenotypes (Figure a), while biologic pleiotropy is induced by phenotypic 
correlation (Figure b); multi-mode pleiotropy is also plausible (Figure c). DE: direct 
effect, ME: mediated effect, SNV: single nucleotide variant. 
 
 
Supplementary Figure 5.4. Directed acyclic graphs (DAGs) used to formulate causal 
mediation analysis for variants rs60505812 and rs73093474. For variant rs60505812, 
BMI is proposed as the mediating phenotype and interleukin(IL)-6 as the outcome. For 
the remaining variant, rs60505812, waist to hip ratio (WHR) was proposed as the 










Obesity is one of the major public health crises of our time378,379 and has steadily 
increased worldwide6, affecting urban and rural dwellers9, children and adults10, and men 
and women  alike9. Many factors have been associated with the increased incidence of 
obesity, including increased access to cheap, high-calorie processed foods380, reduced 
physical activity381, changes in the environment382, and increased exposure to chemicals383, 
among other potential contributors. Increased obesity, particularly abdominal obesity19, has 
been associated with the increased incidence of various adverse metabolic disorders17,18,384 
including insulin resistance20, hypertensive blood pressure21, elevated lipid levels22, and 
hormonal dysregulation18. These metabolic disorders, in turn, have been associated with 
the increased susceptibility to cardiovascular diseases23. 
1. Inflammation-adiposity association 
The underlying mechanisms that link obesity to cardiovascular diseases remain subject 
to debate50-52, and certain hypotheses, including insulin resistance-induced arterial 
stiffness53 and kidney-promoted hemodynamic imbalances55, have received wider attention 
than others. However, changes in the local distribution of nutrition-sensitive62 adipose 
tissue (due to the increased accumulation of visceral fat)59 have been associated with 
altered morphologic and hormonal profiles60,61, and the resulting upregulation in 
inflammation68,69 is thought to be a root cause of a large proportion of metabolic disorders. 
An increased number (hyperplasic) of enlarged (hypertrophic) adipocytes promotes the 
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increased production of cytokines, including IL-6 and IL-878,79. Cytokines attract 
macrophages81,82, which, in turn, can activate the intracellular signals responsible for 
upregulating the innate immune response87 and trigger the inception of atheromatic 
processes that seed arterial lipid plaque formation. 
In contrast, compelling evidence has also suggested that insulin resistance88,89and 
increased circulatory91 and hypothalamic inflammatory responses92,93 might precede the 
development of obesity. An increase in inflammatory mediators has been shown to predict 
future obesity outcomes385. These seemingly contradictory observations necessitate a more 
nuanced exploration of the relationships between obesity and immunity. 
2. Rule of genetics and ancestry in inflammation-adiposity association  
Although some of these findings might merely reflect circular feedback mechanisms, the 
complex natures of both phenotypic domains might also indicate the involvement of other 
mechanisms. Changes in both adiposity and inflammation may be mediated by common 
pathways, a proposition that is supported by the observed overlap between genetic variants 
associated with both adiposity and inflammatory markers110,111,114-116. The observations of 
increased inflammatory responses following the upregulation of adiposity gene 
expression112,113 and weight-gain associated inflammatory gene activation118,119 further 
support the idea that these pathways may share common mediators. The existence of 
pervasive124 and multi-potent ‘pleiotropic genetic variants’122 have been hypothesized, 
which could provide insight into the shared biology and pathophysiological processes that 




However, potential pleiotropic variants have not yet been sufficiently explored. 
Methodological issues, including difficulties distinguishing biologic pleiotropy (in which 
a genetic locus is independently associated with multiple phenotypes) from mediated 
pleiotropy (in which a genetic locus is correlated with a phenotype but may not be 
causal)127, ascertainment bias due to co-occurring traits135, phenotypic 
misclassifications136, variations in allelic structures, or difficulty to identify shared 
controls137, and ambiguity when a causal variant is identified as a regulatory, non-coding 
SNP138, can all pose significant barriers to identifying share pleiotropic regulators. The 
most important challenge has been the limited inferential utility of variants identified 
through GWAS for pleiotropy testing. A disproportionately large proportion of existing 
GWAS have been performed on largely European ancestry populations139,140.  
The significance of genetic architecture can be further highlighted by the differential 
distributions of adiposity and inflammation among distinct genetic ancestry groups that are 
otherwise comparable142-144. Hispanics/Latino (HLA) populations, in particular, have been 
noted to present an increased incidence of cardiometabolic abnormalities145, with a diabetes 
prevalence that is 2.5-fold the level reported among non-Hispanic Whites (NHW)25, and 2 
in 3 HLA adults present with abnormal lipid levels26.  
Although some of this discrepancy could be explained by an increased prevalence of the 
obesity11,14, differences in inflammation levels have persisted, even in adiposity-adjusted 
analyses142,146. These disparities extend to the “Hispanic paradox”, in which the 
cardiovascular mortality rate among this population is lower than other populations, despite 
elevated metabolic risk factors27,28 and have not yet been sufficiently explained by other 
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contributing factors30,33. These findings underscore the need to re-focus on the important 
but sparsely explored contribution of genetics to obesity and inflammation interaction34.  
3. Study object 
The aims of this study were: to identify genetic loci with potential evidence of pleiotropic 
effects across inflammatory factors, including CRP, IL-6, IL8, and fibrinogen, overall 
obesity (BMI), and central adiposity (WC & WHR) domains, in an HLA population (Aim 
1); to fine-map potential pleiotropic loci and distinguish likely causal variants (Aim 2); and 
to evaluate whether observed signals demonstrate independent associations with both 
phenotypic domains (i.e., biologic pleiotropy) or whether the association is induced via 
phenotypic correlations (i.e., mediated pleiotropy, Aim 3). 
4. Cameron County Hispanic Cohort 
The population examined in this study was the CCHC. Most of these participants self-
identify as Mexican Americans. This cohort is characterized by a high prevalence of 
obesity and cardiometabolic abnormalities166,167, with increased susceptibility to adverse 
health events. The prevalence of obesity in this population was higher than the national 
HLA average, as reported by the CDC for the 2017–2018 period275 (45% nationally vs. 
>75% in this study). 
A total of 3,313 samples were examined in this study. The number of SNPs identified for 
genetic testing was >9 million. Analyses of ancestry PCs showed that the majority of PCs 
clustered predominantly with Mexican populations, with fewer individuals aligning with 




5. Genetic signals 
The GWAS analyses showed that two regions on chromosomes 6 and 8 exceeded the 
GWAS significance level (p-value < 5 × 10−8) for sex-combined meta-analyzed WHR 
results; the GWAS-identified significant SNPs in the novel locus are located in regions 
near LRFN2 and LOC101929555, and have not been previously recorded in GWAS 
libraries. Variants in LRFN2 have been positively associated with BMI257,258, type 2 
diabetes259, lipid profiles260, cognitive abilities261, and WHR262.  
The absence of GWAS-identified significant associations in regions that have been 
widely reported to be associated with anthropometric and inflammatory traits263,264 may be 
the result of ancestry-specific patterns, similar to findings from other studies that have 
reported ethnic differences in genetic associations268-271. However, caution must be 
exercised when making any inferences because differences in the LD structure239, 
statistical power238, and SNP coverage272 among studies can all induce variations in the 
GWAS signal.  
6. Evidence for pleiotropy 
Pleiotropy assessments were performed using the aSPU199 testing method. Although no 
pleiotropic signals were observed at the GWAS significance level, at least five signals, on 
chromosomes 1, 3, 12, 18 and 19, were identified that suggested the presence of SNPs with 
strong pleiotropic p-values (< 5 × 10−6). Although the signals on chromosomes 1 and 19 
were driven by solitary variants in each instance, the suggestive loci in the remaining three 
chromosomes were robust to sensitivity analyses and contained clusters of SNPs with 
strong pleiotropy p-values.  
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A review of the GWAS catalogue revealed an extensive number of variants with varying 
degree of LD with SNPs within the three suspected pleiotropic regions that were previously 
reported in association with a range of metabolic traits. All three regions contained variants 
associated with inflammatory diseases, anthropometric measures, and energy intake. 
Additionally, for the loci identified on chromosome 3, a considerable number of variants 
were in LD with variant in the region that were previously identified for brain functions 
and neurological diseases.  
The fine-mapping of these three suspected pleiotropic regions (on chromosomes 3, 12, 
and 18) was performed, incorporating the summary statistics from pleiotropy analyses, LD 
structures, and functional annotations with regulatory and coding features293,294, which 
distinguished 22 variants with posterior causality probabilities greater than 50% among the 
7,326 total variants assessed across all 3 regions.  
None of the index SNPs, which had the most significant pleiotropy p-values, were 
identified among the credible causal variant sets in each region, which could be due to 
several possibilities, including the high correlation with several significant variants, the 
index SNP serving as a proxy for the true ‘causal variant’312, interactions with distant 
topologically associated domain (TAD)313 variants, or the presence of multiple signals. 
However, a potential second (independent) signal was only observed for the suspected 
pleiotropic locus identified on chromosome 18.  
7. Characteristics of likely pleiotropic signals 
The clear majority of likely causal variants identified in each of the three regions were 
intronic, nonsense-mediated decay (NMD) variants, which overlapped with six different 
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genes, including sulfatase-modifying factor 1 (SUMF1) on chromosome 3, interleukin 1-
associated receptor kinase (IRAK4) and transmembrane 117 (TMEM117) on chromosome 
12, and serpin family B 10 (SERPINB10), SERPINB2, and histocompatibility minor serpin 
domain-containing (HMSD) on chromosome 18.  
NMD variants play regulatory roles, quality-checking gene expression errors by 
eliminating messenger ribonucleotide (mRNA) molecules that contain premature 
termination codons328. Growing evidence has suggested that variations and tissue-specific 
differences in NMDs can alter the underlying pathologies of genetic diseases329-331. 
Notably, interactions between NMDs and protein-coding variants have been linked with 
an increased risk of developing obesity and type 2 diabetes, as reported in one recent trans-
ancestry cohort332. For instance, in a clinical study, a patient with early-onset obesity was 
characterized with a mutation-induced malfunction of the NMD surveillance pathway, 
which affected Pro-opiomelanocortin (POMC) gene regulation; this gene is involved in a 
wide range of activities, including body-weight regulation333. The results from this study 
further underscored the importance of NMD variants in the context of pleiotropy.  
Pleiotropy association studies cannot distinguish whether an observed association 
between a genetic variant and a phenotype occurs due to direct (i.e., biologic pleiotropy) 
or indirect effects (i.e., mediated pleiotropy) due to phenotypic correlations with the 
primary trait. Mediation analysis refers to a type of conditional analysis, in which the total 
effect between a predictor and an outcome is divided among several factors that contribute 
to the association and relies on counterfactual principles208. Using this framework, the 
causal effects can be viewed as the difference between two potential phenotypic outcomes, 
depending on whether an individual harbors the risk alleles (at the same time).  
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In addition to the 3 identified index SNPs, which featured the lowest pleiotropic p-values 
for each locus with evidence for pleiotropy, all 22 fine-mapped variants with high posterior 
causality probabilities were fit into univariate regression models using the phenotypes as 
predictors. Those variants in tighter LD with their respective index SNPs exhibited 
consistent and significant associations with multiple phenotypes in these univariate 
regressions, and those with the lowest pleiotropic p-values and regulatory features 
associated with adipose tissue were selected for in-depth causal mediation analysis.  
The mediation analysis indicated that rs60505812 was independently associated with 
both an inflammatory marker (IL-6) and an adiposity measure (BMI), even after adjusting 
for potential confounders like age, sex, physical activity level, alcohol consumption, and 
current smoking status, which is consistent with the biologic pleiotropy model.  
Although no direct association between SUMF1 and metabolic traits has previously been 
reported, variants in this gene have been suggested to be associated with inflammatory 
diseases, including chronic obstructive pulmonary disease (COPD)318. Additionally, 
steroid sulfates play functional roles in energy homeostasis and inflammation319. The 
overexpression of human steroid sulfatase in the adipose tissue of transgenic male mice 
and female mice that underwent ovariectomy exacerbated metabolic phenotypes, resulting 
in weight gain and the accumulation of fat mass, worsened insulin sensitivity, and altered 
energy expenditures386.  
8. The functional evaluation of likely pleiotropic variants 
The functional assessment of rs60505812 with Haploreg demonstrated an annotation 
associated with histone 3 lysine 4 trimethylated (H3K4me3)374 in fetal adipose cell nuclei. 
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H3K4me3 regulates gene expression by altering the accessibility of genes to promote 
mRNA transcription375 and has generally been associated with actively transcribed genes 
in animal models387. H3K4me3 is also known to play a significant role in the genetic 
regulation of stem cell potency387. H3K4me3 has been extensively observed on 
nucleosomes at the 5’ end of eukaryotic genes undergoing active transcription by RNA 
polymerase II388. A regulatory annotation in fetal nuclei would suggest functional 
associations with pathway(s) upstream to a wide range of metabolic traits, resulting in 
pleiotropic properties at protein or variant levels. However, further assessments remain 
necessary to establish the precise level at which the suggestive signal operates.  
For the variant rs73093474, on chromosome 12, mediation analysis indicated both a 
direct association with CRP (Table 6.3) and an indirect association (via WHR) in the 
covariate-adjusted models, which demonstrated concurrent biologic and mediated 
pleiotropy. In contrast with rs60505812, rs73094374 has a regulatory annotation with the 
mono-methylated H3K4me1-enhancer in adipose cell nuclei, in addition to skeletal muscle 
and brain tissues. H3K4me1 is the primary modification used to predict whether an 
identified SNP is a potential enhancer (booster) of gene expression376.  
This SNP was also an NMD variant, intronic to transmembrane 117 (TMEM117), which 
encodes a similarly named protein. This gene has been associated with endoplasmic 
reticulum stress (ER-stress) and mitochondria-mediated apoptotic cell death322. Obesity-
induced ER-stress has been shown to induce inflammation in adipose tissue377. In 
experimental studies examining mice, sustained fat accumulation interrupted ER 
homeostasis and induced the unfolded protein response (UPR)389. Unfolded proteins within 
the ER lumen activate the ER stress pathway390, and lipid-sensitive transmembrane 
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proteins act as sensors for unfolded proteins391,392. Elevated levels of UPR activation have 
been observed in adipose tissue from obese individuals393 and has been suggested to serve 
as a potential mechanism that might link obesity with inflammation and insulin 
resistance394,395.  
The regulatory annotation associated with H3K4me1 combined with the suggested 
association with UPR-induced ER-stress activity in adipocytes suggest that the biological 
effects of rs73093474 (or the signals it represents) may be relatively tissue-specific, 
compared with those for rs60505812, and less likely to act upon multipotent pathways. 
Further genetic and functional studies in larger settings and varied populations are 
warranted before concrete biological inferences are made.  
9. Study strengths and limitations 
The present study had notable limitations. The sample size used for this study was small. 
Adiposity and inflammation traits are highly polygenic and, therefore, the effect of any 
given genetic variant on the overall phenotype is small, and adequate statistical power is 
necessary to isolate signals. GWAS performed in larger samples present considerably 
improved detection power compared with smaller samples396. The general absence of 
significant GWAS results in this study can largely be attributed to insufficient detection 
power. However, the study incorporated a pleiotropy test that served the dual aims of 
evaluating pleiotropy among correlated phenotypes and increasing the statistical power for 
locus discovery. Previous studies have illustrated133,397-399 that harnessing pleiotropy could 
successfully increase statistical power. 
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Although this study only included a discovery cohort, the analysis did account for 
multiple factors that could affect the generalizability of observed signals400, including each 
variant’s effective sample size and ancestry architecture401. Furthermore, low frequency 
and rare variants with MAF  <5% ,  were excluded from the analysis to improve the 
likelihood of replicability.  
The study could not distinguish whether suggestive pleiotropic signals acted at specific 
levels or were associated with multi-potent pathways that affected a wider range of 
phenotypic traits. Generally, trans-regulatory SNPs act at the variant level, whereas cis-
regulatory and coding SNPs act at the protein (i.e., gene) and tissue levels402. The precise 
characterization of pleiotropic signals requires insight from expression quantitative trait 
(eQTL) analysis which seeks to examine SNPs that affect the mRNA expression levels, or 
more relevently candidate SNP-mRNA study. However, functional annotation evaluation 
was able to provide suggestive evidence for possible functional roles associated with likely 
causal variants. For instance, the fetal nuclei H3K4me3 annotation for rs60505812 was 
suggestive of potential pleiotropic effects at either variant or protein levels. 
The present study also had major strengths. This study is the first comprehensive 
assessment of pleiotropy relationships between adiposity and inflammation traits in an 
HLA or any population. The results provided suggestive evidence for the regulatory effects 
of identified genetic variants on metabolic pathways and highlighted the complexity and 
interrelatedness of seemingly independent phenotypic traits.  
The intentional selection of a genetically tri-admixed HLA population151 with shorter 
haplotypes compared with European ancestry (EA) populations155 presented opportunities 
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for precise fine-mapping154, which greatly reduced the number of SNPs identified for 
causal evaluations157,158.  
Rigorous association tests, which incorporated pairwise kinship structures, improved 
genetic associations’ estimates. The integrative analytical framework that was used for this 
study is innovative; and the combination of various steps, including GWAS, pleiotropy 
assessments, fine-mapping, functional evaluations, and causal mediation analysis 
collectively improved the biological interpretation of the results. 
10. Study summary and conclusion 
The characterization of overlapping genetic pleiotropy between inflammatory and 
adiposity pathways is essential for improving our understanding of the etiology of the 
various metabolic pathways that regulate cardiovascular disease development. This 
research provided a systematic assessment of potential variants that exert pleiotropic 
effects on inflammatory and adiposity traits. The analysis distinguished a novel locus on 
chromosome 6 associated with WHR outcomes in sex-combined results.  
The examination of 3 loci with suggested pleiotropy resulted in the isolation of 22 
variants with high posterior causal probabilities, including 2 SNPs on chromosomes 3 
(rs60505812) and 12 (rs73093474) that exhibited regulatory features associated with 
adipose tissue. The identification of likely pleiotropic variants indicated that 1) a 
considerable degree of overlapping genetic pleiotropy exists between adiposity and 
inflammation, and 2) evidence exists to support both the direct and independent pleiotropic 
effects of likely causal variants on both phenotypic domains, in addition to the potential 
mediated pleiotropy.  
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The results showed the potential of these genetic variants to provide biological insight, 
which might inform the development of preventive and clinical strategies intended to 
improve the cardiovascular outcomes of HLA populations, and by extension, improve 
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